

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Impact of PCSK9-monoclonal antibodies on circulating hs-CRP levels: a systematic review and meta-analysis of randomized controlled trials

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022348
Article Type:	Research
Date Submitted by the Author:	14-Feb-2018
Complete List of Authors:	Cao, Ye-Xuan; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College Li, Sha; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Division of Dyslipidemia Liu, Hui-Hui; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Division of Dyslipidemia Li, Jian-Jun; Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College
Keywords:	PCSK9, monoclonal antibody, hs-CRP, meta-analysis

SCHOLARONE™
Manuscripts

Only

1
2
3 **BMJ Open**

2018-02-12

4
5
6
7 **Title:** Impact of PCSK9-monoclonal antibodies on circulating hs-CRP levels: a systematic
8 review and meta-analysis of randomized controlled trials
9

10
11
12 **Running Title:** PCSK9-mAb and hs-CRP
13

14
15
16
17 **Authors:** Ye-Xuan Cao, MD*, Sha Li, MD, PhD*, Hui-Hui Liu, MD*, Jian-Jun Li, MD, PhD*
18
19

20
21
22
23 **Affiliations:** *Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu
24 Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical
25 Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing 100037, China.
26
27
28

29
30
31
32
33 **Correspondence:** Professor Jian-Jun Li, MD, PhD, FESC, FACC. Division of Dyslipidemia,
34 State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for
35 Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical
36 College, BeiLiShi Road 167, Beijing 100037, China. Tel: 86+10+88396077; Fax:
37 86+10+88396584. E-mail: lijianjun938@126.com.
38
39
40
41
42
43

44
45
46
47 **Total word count:** 2882
48

49
50 **Number of tables/figures:** tables 1; figures 3
51
52
53
54
55
56
57

ABSTRACT

Objective To evaluate the potential effects of proprotein convertase subtilisin/kexin type 9 monoclonal antibody (PCSK9-mAb) on high-sensitivity C-reactive (hs-CRP) concentrations.

Design A systematic review and meta-analysis of randomized controlled trials.

Data sources PubMed, MEDLINE, The Cochrane Library databases, clinical trials registries websites and recent conferences were searched from inception to January 2018.

Eligibility criteria for selecting studies All randomized controlled trials that reported changes of hs-CRP were included.

Results Ten studies involving 4198 participants were identified. PCSK9-mAbs showed a slight efficacy in reducing hs-CRP (-0.04mg/L, 95%CI:-0.17 to 0.01), but no statistical difference was found. Subgroup analyses showed no significant effect when stratified by PCSK9-mAb types (Alirocumab:0.12mg/L, 95% CI:-0.18 to 0.43; Evolocumab:0.00 mg/L, 95% CI:-0.07 to 0.07; LY3015014:-0.48mg/L, 95% CI:-1.28 to 0.32; RG7652:0.35mg/L, 95% CI:-0.26 to 0.96), treatment duration (≤ 12 w:0.00mg/L, 95% CI:-0.07 to 0.07; >12 w:-0.11mg/L, 95% CI:-0.45 to -0.23), participant characteristics (familial hypercholesterolemia:0.00mg/L, 95% CI:-0.07 to 0.07; non-familial hypercholesterolemia:0.07mg/L, 95% CI:-0.12 to 0.26; mix:-0.48mg/L, 95%CI:-1.28 to 0.32) and treatment methods (monotherapy:0.00mg/L, -0.08 to 0.07; combination-therapy:-0.08mg/L, -0.37 to 0.21). Meta-regression analyses identified no significant linear correlation between baseline age ($p=0.673$), sex ($p=0.645$) and low-density lipoprotein cholesterol reduction ($p=0.339$).

Conclusions Although previous study showed a slightly reduced effect of PCSK9-mAbs on hs-CRP, the results of this updated meta-analysis suggested that PCSK9-mAbs had no significant impact on circulating hs-CRP levels.

Keywords: PCSK9; monoclonal antibody; hs-CRP; meta-analysis

Strengths and limitations of this study

- This is a comprehensive systematic review and meta-analysis of randomized controlled trials, conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.
- We used a broad search strategy and identified 10 studies that reported changes of high-sensitivity C-reactive during proprotein convertase subtilisin/kexin type 9 monoclonal antibody treatment.
- Studies with moderate heterogeneity and lack of individual level data.

Introduction

Cardiovascular disease is the greatest burden of global health, which is characterized by atherosclerosis¹. Atherosclerosis is a chronic and progressive inflammatory disease, including endothelial dysfunction, lipid accumulation in the arterial wall and leukocyte infiltration, which leads to luminal stenosis, plaque rupture and acute coronary syndrome (ACS)². Apart from well-established dyslipidaemia theory, inflammation also plays an important role in the initiation and progression of atherosclerosis³. Recently, CANTOS trial reported that anti-inflammatory therapy by canakinumab, a therapeutic monoclonal antibody targeting interleukin-1 β (IL-1 β), significantly reduced the primary cardiovascular end points⁴.

Hs-CRP (high-sensitivity C-reactive protein) is the most intensively investigated inflammatory biomarker and shows an extensive clinical application. Hs-CRP is an 11,800 Da molecular synthesized by hepatocytes in response to interleukin 6 (IL-6)⁵. Several studies revealed that hs-CRP concentration was relatively constant in an individual, making it an ideal inflammatory biomarker⁵. Increasing studies have confirmed that hs-CRP is a predictive factor for assessing the progression of atherosclerotic disease and future adverse cardiovascular events (CE)^{6,7}. Moreover, previous studies also indicated that hs-CRP may have pro-inflammatory effects and play a direct role in progression of atherosclerosis^{8,9}. Many studies demonstrated that administration of statins may modify hs-CRP and other pro-inflammatory cytokine concentrations with decreasing CEs^{10,11}.

Proprotein convertase subtilisin/kexin type 9 (PCSK9), a 73-kDa protein secreted by liver, regulates the activity of low-density lipoprotein receptor (LDLR) expressing in hepatocellular surface¹². Multiple studies revealed that PCSK9 binds to LDLR and increases its degradation to block the cholesterol homeostasis, resulting in elevated plasma low-density lipoprotein cholesterol (LDL-C) levels^{13,14}. PCSK9 monoclonal antibody (PCSK9-mAb)

1
2
3 decreased LDL-C concentrations by up to 70% and reduced the rate of CEs¹⁵. Therefore,
4 PCSK9-mAb has emerged as the most powerful lipid-lowering drugs currently. Although the
5 effect of PCSK9 on LDL-C has been established, its role in inflammation has not been fully
6 investigated. A number of experimental studies found that PCSK9 could enhance
7 inflammatory reaction to promote the progression of atherosclerosis and down-regulated
8 PCSK9 expression led to the reduction of inflammation^{16,17}. A meta-analysis published two
9 years ago found that PCSK9-mAbs had no effect on serum hs-CRP¹⁸. However, this
10 meta-analysis did not perform sufficient subgroup analyses to our knowledge. Besides, a
11 recent published study with limited sample size found that initial PCSK9 plasma levels are
12 associated with hs-CRP levels in patients with ACS¹⁹ and some kinds of PCSK9-mAbs
13 showed a reduction in hs-CRP levels²⁰. Hence, whether PCSK9-mAbs could decrease
14 circulating hs-CRP levels should be intensively examined.

15
16 To further explore the efficiency of PCSK9 inhibitors on serum hs-CRP levels, we
17 performed this meta-analysis including all published randomized controlled trials (RCT)
18 published till January 2018.

19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 **Methods**

38 39 40 **Literature search**

41 The present study was designed according to the guidelines of the 2009 Preferred Reporting
42 Items for Systematic Reviews and Meta Analyses (PRISMA) statement²¹. To identify all
43 RCTs that assessed the effects of PCSK9-mAbs on circulating hs-CRP levels, we
44 comprehensively searched PubMed, MEDLINE, and the Cochrane Library database up until
45 January 2018. We also searched the clinical trials registries websites. The search terms we
46 used included the following: (AMG145 or Evolocumab or REGN727 or SAR236553 or
47 Alirocumab or RN316 or bococizumab or RG7652 or LY3015014 or PCSK9 antibody or
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 anti-PCSK9) AND (randomized controlled trial OR randomized OR randomly). Meanwhile
4
5 manual search was performed for relevant studies including references lists, relevant review
6
7 articles and commentaries. No language restriction was used and non-English articles were
8
9 translated.

10 11 12 13 **Study selection**

14
15 Original studies met the following criteria would be included: the design was phase 2 or
16
17 phase 3 double-blind RCTs with longer than 8 weeks treatment duration; human participants
18
19 were randomly assigned to PCSK9-mAbs group versus control group with or without other
20
21 lipid-lowering therapy; outcomes included percentage changes of hs-CRP from baseline.
22
23 Studies were excluded if they were duplicate publications, review articles, non-human studies,
24
25 observational studies, lack of adequate information on outcomes or lacking control group.
26
27 Two investigators (YC and SL) independently screened and selected the eligible studies.
28
29 Disagreements were resolved by discussion with a third investigator.
30
31
32
33
34

35 **Data Extraction**

36
37 A standardized extraction form was used to extract the following items by two investigators
38
39 (YC and HL) independently: trial name/first author, year of publication, type of intervention,
40
41 follow-up period, treatment duration, number of patients, participant characteristics,
42
43 background lipid-lowering therapy, types and doses of PCSK9-mAbs, LDL and hs-CRP
44
45 levels at baseline and changes. We included the final reported follow-up point if a trial
46
47 contains several time points. If necessary, further information was required from
48
49 correspondence author.
50
51
52
53

54 **Quality Assessment**

1
2
3 We used Cochrane Collaboration's tool and Jadad score to assess the data and the
4 methodological quality of included RCTs. For Cochrane Collaboration's tool, the following
5 items were performed: random sequence generation (selection bias), allocation concealment
6 (selection bias), blinding of participants and personnel (performance bias), blinding of
7 outcome assessment (detection bias), incomplete outcome data (attrition bias), selective
8 reporting (reporting bias) and other sources of bias. The judgments were classified as 'low
9 risk', 'high risk', and 'unclear risk' of bias. The 5-point Jadad score included the following
10 items: basis of randomization (0 to 2 points), double blinding (0 to 2 points), and withdrawals
11 and dropouts (0 to 1 points). Studies with a score ≥ 3 points are considered to be high quality.
12 Two investigators (YC and HL) independently assessed the quality of each study.
13 Disagreements were resolved by discussion with a third investigator.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29 **Data Synthesis and Statistical Analysis**

30 All analyses were analyzed according to the intention-to-treat principle. For all efficacy
31 outcomes, changes in hs-CRP concentrations were expressed as weighted mean difference
32 (WMD) and 95% confidence interval (CI). All the data were standardized and expressed by
33 mg/mL. Standard deviation could be calculated from CI, interquartile range or standard error
34 according to formulas in the Cochrane Handbook for Systematic Reviews of Interventions if
35 not reported.
36
37
38
39
40
41
42
43

44 Heterogeneity was assessed by the Cochran Q test and the I^2 statistic, and we considered
45 $I^2 < 25\%$ as representing low heterogeneity and $I^2 > 75\%$ as representing at high heterogeneity.
46 Outcomes were calculated by fixed-effects model under no or low to moderate inconsistency
47 ($I^2 < 50\%$); otherwise, the data was pooled based on a random-effects model. Subgroups were
48 applied to reduce the heterogeneity if $I^2 \geq 50\%$, such as PCSK9-mAb types, treatment
49 duration and participant characteristics. In order to explore the resource of heterogeneity,
50
51
52
53
54
55
56
57

1
2
3 sensitivity analysis was conducted by omitting studies in turn to evaluate the consistency of
4 the results. Meta-regression analyses were performed to the contribution of participant
5 characteristics and reductions in LDL-C concentrations. Publication bias was assessed with a
6 funnel plot and Egger's test.
7
8
9

10
11 All analyses were conducted with Review Manager Version 5.3 (Copenhagen: The
12 Nordic Cochrane Centre, The Cochrane Collaboration, Denmark) and Stata 14.0 (Stata
13 Statistical Software: College Station, TX: Stata Corp LP). P value <0.05 was considered to be
14 statistically significant.
15
16
17
18
19

20 21 22 **Results**

23 **Study selection and Characteristics**

24 The initial search identified 575 articles. After screening the titles and abstracts, 339 were
25 excluded and 236 studies were retrieved for full-text identification. We further excluded 135
26 studies, of which 58 were pooled or meta-analysis, 2 studies were not RCTs and 13 was phase
27 1 trials, 16 were open label trails and 42 without adequate information. Finally, ten
28 studies^{20,22-30} were included in this meta-analysis. Figure 1 shows flow diagram of selection
29 process.
30
31
32
33
34
35
36
37
38

39 These ten studies were published between 2012 and 2017 from different countries with
40 low risk of bias, of which 5 were phase 2 studies and 5 were phase 3 studies (Table 1). In
41 total, 4198 participants were included, comprising 2728 individuals in the PCSK9-mAb
42 group and 1470 in the control group. Alirocumab (SAR236553/REGN72 7) was used in 4
43 arms and 11 arms applied Evolocumab (AMG 145). Five arms managed LY3015014 and 2
44 arms used RG7652. Participants of 3 studies were heterozygous familial
45 hypercholesterolemia (HeFH), 1 study contained homozygous familial hypercholesterolemia
46 (HoFH) patients, and the remaining 6 trials enrolled non-FH or hypercholesterolemia
47
48
49
50
51
52
53
54
55
56

1
2
3 individuals. Most of the treatment duration ranged from 12 to 24 weeks and the longest
4
5 treatment duration was 78 weeks. Apart from DESCARTES trial which co-administered with
6
7 atorvastatin, another 9 studies used PCSK9-mAb as monotherapy. Baseline characteristics,
8
9 including circulating hs-CRP levels, were similar between PCSK9-mAbs and control groups
10
11 within each study. The characteristics of these trials and participants are summarized in Table
12
13 1. All these studies had a relatively high quality evaluated by the Jadad score and low risk of
14
15 bias (online supplementary Table 1 and online supplementary Figure 1, 3 scores=5, 6
16
17 scores=4).

22 **Efficiency outcomes of PCSK9-mAbs on hs-CRP**

23
24 A total of 4198 participants were included in the analysis of efficiency of PCSK9-mAbs on
25
26 plasma hs-CRP concentrations before and after treatment. When data were pooled,
27
28 PCSK9-mAbs showed a slight efficacy in reducing hs-CRP (WMD: -0.04mg/L, 95%CI: -0.17
29
30 to 0.01), but no statistical difference was found compared with control treatment (Figure 2).
31
32 There was a moderate heterogeneity between each study ($I^2=57.4%$, $P=0.0001$), so the
33
34 random-effects model was selected.
35
36

37
38 To assess the potential discrepancy, we applied the subgroup analysis based on the
39
40 characteristics of trials and participants (Figure 3 and online supplementary Figures 2-5).
41
42 Although the efficiency of LY3015014 was a mild higher (-0.48 mg/L, 95% CI:-1.28 to 0.32),
43
44 there was no difference between these four antibodies (Alirocumab: 0.12 mg/L, 95% CI:
45
46 -0.18 to 0.43; Evolocumab: 0.00 mg/L, 95% CI: -0.07 to 0.07; RG7652: 0.35 mg/L, 95% CI:
47
48 -0.26 to 0.96). When studies were classified by treatment duration, the hs-CRP reduction
49
50 showed no difference in less than 12 weeks duration groups (0.00 mg/L, 95% CI: -0.07 to
51
52 0.07) and above 12 weeks duration groups (-0.11mg/L, 95% CI: -0.45 to -0.23). There was a
53
54 statistically non-significant reduction in circulating hs-CRP with use of PCSK9 antibodies
55
56

1
2
3 compared with control treatment when categorized to participant characteristics (FH: 0.00
4 mg/L, 95% CI: -0.07 to 0.07; non-FH: 0.07 mg/L, 95% CI: -0.12 to 0.26; mix: -0.48 mg/L,
5 95%CI: -1.28 to 0.32). The analysis stratified by treatment method also supported the results
6
7 that no differential effect of PCSK9-mAb therapy on plasma CRP concentrations was
8
9 observed (monotherapy: 0.00 mg/L, 95%CI: -0.08 to 0.07 vs combination-therapy: -0.08
10
11 mg/L, 95%CI: -0.37 to 0.21).
12
13
14
15

16 17 18 **Sensitivity analysis and publication bias**

19
20 The sensitivity analysis for all outcomes in the comparison was conducted by gradually
21
22 removing each study, but the results did not change meaningfully (online supplementary
23
24 Figure 6). Neither funnel plots nor Egger's regression test ($p=0.913$) showed publication bias
25
26 (online supplementary Figure 7).
27
28
29
30

31 **Meta-regression analyses**

32
33 We used meta-regression analysis to assess the association between changes in hs-CRP and
34
35 baseline age, sex and average LDL changes (online supplementary Figure 8). No statistically
36
37 significant relationship between baseline age, sex and hs-CRP changes were observed.
38
39 Likewise, LDL lowering effects had no impact on hs-CRP lowering.
40
41
42
43

44 **Discussion**

45
46 The results of this comprehensive meta-analysis, based on 10 RCTs encompassing 4198
47
48 participants, suggested that short-term PCSK9-mAb therapy had no impact on circulating
49
50 hs-CRP concentrations. In the subgroup analysis, we found no difference between
51
52 PCSK9-mAb types, treatment duration, participant characteristics and treatment methods.
53
54

55
56 Atherosclerosis is a chronic progressive disorder and its pathophysiology is complex. In

1
2
3
4 addition to well-established imbalanced lipid metabolism, growing evidence has suggested
5
6 that inflammation played a major role in the formation and progression of atherosclerosis,
7
8 including vasomotor dysfunction, endothelial cell injury, adhesion and transendothelial
9
10 migration of monocytes and plaque rupture². Numerous pro-inflammatory cytokines, such as
11
12 tumor necrosis factor-alpha (TNF- α), interleukin 1 (IL-1), intercellular cell adhesion
13
14 molecule-1 (ICAM-1), and CRP have been shown to drive the disease progression³¹.
15
16 However, most anti-inflammatory drugs showed no positive effect in reducing the burden of
17
18 atherosclerosis in human studies³². Fortunately, evidence from CATONS found that
19
20 canakinumab significantly reduced hs-CRP levels and cardiovascular outcomes after
21
22 follow-up of 3.7 years, which directly confirmed the inflammatory hypothesis⁴.
23
24
25
26
27

28 A number of studies indicated that hs-CRP could independently predict major CEs⁶.
29
30 Framingham study found that men and women in the highest quartile of CRP respectively
31
32 had twice and three-times the risk of stroke compared with those in the lowest after more than
33
34 10-years follow-up³³. NOMAS (the Northern Manhattan Study) reported that >3 mg/L CRP
35
36 was associated with a 1.7-fold increase in cardiovascular outcomes and a 1.55-fold increase
37
38 in mortality³⁴. A recent study showed a positive association between sustained high exposure
39
40 to hs-CRP and CVD risk⁷. Furthermore, hs-CRP also plays a vital role in the development of
41
42 atherosclerosis. Zwaka et al⁸ found that CRP enhanced the transformation from macrophages
43
44 to foam cells by increasing the uptake of native LDL. Previous studies also reported that CRP
45
46 impaired vasodilatation, inhibited the synthesis of nitric oxide synthase, and facilitated
47
48 adhesion of monocyte^{35,36}. Many studies found that statin therapy may reduce hs-CRP and
49
50 other pro-inflammatory cytokine concentrations with decreasing CEs^{10,11}. The JUPITER
51
52
53
54
55
56
57
58
59
60

1
2
3 study applied rosuvastatin on individuals with LDL-C levels below 130 mg/dl but with
4
5 hs-CRP levels ≥ 2 mg/l and found a significant reduction in all vascular events³⁷. That is the
6
7 reason why we chose hs-CRP as an inflammatory biomarker to identify whether
8
9 PCSK9-mAb has an effect on inflammatory status.
10
11

12
13 Although the relationship between PCSK9 and LDL-C was well-established, more and
14
15 more evidence demonstrated its function beyond lipids. In 2010, microarray gene expression
16
17 analysis suggested that PCSK9 affected not only cholesterol metabolism, but also
18
19 inflammation. Experimental studies indicated that PCSK9 could participate in vascular and
20
21 inflammation. Experimental studies indicated that PCSK9 could participate in vascular and
22
23 systemic inflammation¹⁶. PCSK9 enhanced the oxidized low-density lipoprotein (ox-LDL)
24
25 accumulation in macrophages by up-regulating the expression of CD36 and blocked
26
27 cholesterol efflux through lowering ATP-binding cassette transporter (ABCA1) and
28
29 ATP-binding cassette transporter G1 (ABCG1) levels³⁸. In transgenic mice expressing human
30
31 PCSK9 gene, Tavori et al³⁹ observed that atherosclerosis lesion size and local Ly6C^{hi}
32
33 monocytes, the precursors of pro-inflammatory M1 macrophages, significantly increased.
34
35 Clinical studies further supported this hypothesis. Li et al⁴⁰ found that serum PCSK9
36
37 concentrations were associated with white blood cell count independently in CAD patients,
38
39 indicating PCSK9 may be involved in the inflammation process. ATHEROREMO-IVUS
40
41 study reported a positive linearly association between PCSK9 levels and coronary plaque
42
43 inflammation, including amount of necrotic core tissue and plaque volume⁴¹. PCSK9
44
45 concentration was also reported to be a predictor for carotid atherosclerosis in asymptomatic
46
47 adults and for the incidence and severity of CAD independent of conventional cardiovascular
48
49 risk factors^{14,42}.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Since previous studies showed that PCSK9 directly augmented inflammatory cytokines
5
6 expression and atherosclerotic lesion, PCSK9 inhibition may exert anti-inflammatory effects.
7
8 The levels of IL-1, IL-6, TNF- α , and PCSK9 synthesized by THP-1-derived macrophages
9
10 were increased after treated with ox-LDL and PCSK9 small interfering RNA reduced the
11
12 expression of these pro-inflammatory genes through nuclear factor kappa B (NF- κ B)
13
14 Pathway⁴³. In apoE^{-/-} mice, PCSK9 silencing limited the development of atherosclerosis and
15
16 decreased the number of macrophages and the expression of vascular inflammation regulators
17
18 through TLR4/NF- κ B signaling pathway⁴⁴. Pro-inflammatory Ly6C^{hi} monocytes and
19
20 ICAM-1, which enhances the adhesion to the vascular endothelium, were obviously reduced
21
22 after treatment with Alirocumab¹⁷. AT04A anti-PCSK9 vaccine also got the same results that
23
24 anti-PCSK9 therapy could reduce vascular inflammation⁴⁵. Clinically, Bernelot et al⁴⁶ found
25
26 that after 24 weeks of treatment with PCSK9-mAbs, the migratory capacity of monocytes and
27
28 inflammatory responsiveness showed a significant reduction, and anti-inflammatory cytokine
29
30 interleukin-10 levels increased in FH patients, which supported the hypothesis that
31
32 PCSK9-mAb had an anti-inflammatory effect. However, in our study PCSK9 suggested no
33
34 effect on decreasing hs-CRP in both FH participants and non-FH individuals.
35
36
37
38
39
40
41

42
43 Statins are the cornerstone of cardiovascular drugs because of its pleiotropic effects,
44
45 including lipid-lowering and anti-inflammatory effect, which notably reduce CAD risks. The
46
47 CARE trial indicated that pravastatin decreased hs-CRP levels independent of LDL-C⁴⁷.
48
49 AFCAPS/TexCAPs research also got the similar results that statin was clinically effective in
50
51 primary prevention of CAD events by reducing LDL-C and hs-CRP levels⁴⁸. Interestingly,
52
53 unlike statins, although experimental and clinical studies showed that PCSK9 inhibition could
54
55
56
57
58
59
60

1
2
3 reduce atherosclerotic inflammation, in our study PCSK9-mAbs had no significant impact on
4
5 plasma hs-CRP levels. Besides, the same results were also observed in combination of statins
6
7 and PCSK9-mAbs group. Although the results of previous meta-analysis published two years
8
9 ago consistent with ours, the methods of analyses including subgroup analysis were different
10
11 and they might be limited by small sample size and insufficient subgroup analyses. Although
12
13 the exact mechanism between statin and PCSK9-mAb on inflammation is unclear, it is
14
15 notable that the participants in statins therapy had high levels of hs-CRP at baseline, while, in
16
17 PCSK9 inhibition therapy, initial hs-CRP levels were at normal range in recruited individuals.
18
19 Besides, the effective observation of PCSK9-mAb on inflammatory marker in humans may
20
21 be limited by duration. The treatment duration and follow-up period is long in statin therapy,
22
23 but the longest follow-up of PCSK9-mAbs was 78 weeks. Furthermore, no confirmative
24
25 evidence has been found to decline CAD risk by reducing hs-CRP levels alone. Therefore,
26
27 although this meta-analysis indicated a non-effect of PCSK9 on hs-CRP, a large number of
28
29 data suggested that PCSK9 plays a vital role in atherosclerotic inflammation. More
30
31 experimental and clinical researches may be needed to fully understand the impact of
32
33 PCSK9-mAbs on CRP in the future.
34
35
36
37
38
39
40
41
42
43

44 **Limitations**

45
46 First, meta-analysis is a retrospective approach and based on trial level data but not
47
48 on individual level data. Second, study design, treatment duration, follow-up and baseline
49
50 characteristics were different in the studies included. Some studies had a statin run-in period
51
52 which would influence the final results. Third, moderate degree of heterogeneity was obvious
53
54 in several comparisons. However, there was no publication bias and the results were rather
55
56
57
58
59
60

1
2
3 consistent among different subgroups and sensitivity analyses. Fourth, some studies included
4 in this meta-analysis did not provide adequate information about blinding of participants and
5
6
7 personnel.
8
9

10 11 **Conclusions**

12
13 In conclusion, the current evidence suggests that despite intense effect on lipid-lowering,
14 PCSK9-mAbs have no significant impact on circulating hs-CRP concentrations. Hopefully,
15
16 more participants with elevated hs-CRP levels at baseline or with CAD will be recruited in
17
18 large, oncoming RCTs to explore whether PCSK9-mAbs have pleiotropic effects like statins.
19
20
21
22
23
24
25
26
27
28

29 **Acknowledgements**

30
31 Not any.
32
33
34

35 **Contributors**

36
37 JJL contributed to conception and design, acquisition, analysis, and interpretation, and
38
39 critically revised the manuscript. YXC contributed to design, acquisition, analysis, and
40
41 interpretation and drafted the manuscript. SL contributed to acquisition, analysis, and
42
43 critically revised the manuscript. HHL contributed to analysis, interpretation and critically
44
45 revised the manuscript. All the authors read and approved the final version of the manuscript.
46
47
48
49

50 **Funding**

51
52 This work was partially supported by the Capital Health Development Fund (201614035) and
53
54 CAMS Major Collaborative Innovation Project (2016-I2M-1-011) awarded to Dr. Jian-Jun Li,
55
56

1
2
3 MD, PhD. The sponsors had no role in the decision to conduct the meta-analyses, data
4 analysis, or reporting of the results.
5
6
7

8
9 **Competing interests:** None declared.
10

11
12
13 **Patient consent:** Not required.
14

15
16
17 **Ethics approval:** This research is exempt from ethical approval.
18

19
20
21 **Data sharing statement:** No additional data available.
22

23 24 25 26 **Reference**

- 27
28
29 1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to
30 2030. *PLoS Med.* 2006;3:e442.
31
- 32
33
34 2. Ross R. Atherosclerosis--an inflammatory disease. *N Engl J Med.* 1999;340:115-26.
35
- 36
37
38 3. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker
39 discovery and risk prediction. *Clin Chem.* 2008;54:24-38.
40
- 41
42
43 4. Ridker PM, Everett BM, Thuren T, *et al.* Antiinflammatory Therapy with Canakinumab for
44 Atherosclerotic Disease. *N Engl J Med.* 2017;377:1119-31.
45
- 46
47
48 5. Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause
49 of cardiovascular diseases. *Med Hypotheses.* 2004;62:499-506.
50
- 51
52
53 6. Li JJ, Li S, Zhang Y, *et al.* Proprotein Convertase Subtilisin/Kexin type 9, C-Reactive Protein,
54 Coronary Severity, and Outcomes in Patients With Stable Coronary Artery Disease: A
55 Prospective Observational Cohort Study. *Medicine.* 2015;94:e2426.
56

- 1
2
3
4 7. Wang A, Liu J, Li C, *et al.* Cumulative Exposure to High-Sensitivity C-Reactive Protein
5 Predicts the Risk of Cardiovascular Disease. *J Am Heart Assoc.* 2017; 6: e005610.
6
7
- 8
9 8. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein
10 uptake by macrophages: implications for atherosclerosis. *Circulation.* 2001;103:1194-7.
11
12
- 13
14 9. Zhang YX, Cliff WJ, Schoefer GI, *et al.* Coronary C-reactive protein distribution: its relation to
15 development of atherosclerosis. *Atherosclerosis.* 1999;145:375-9.
16
17
- 18
19 10. Li JJ, Fang CH. Effects of 4 weeks of atorvastatin administration on the antiinflammatory
20 cytokine interleukin-10 in patients with unstable angina. *Clin Chem.* 2005;51:1735-8.
21
22
- 23
24 11. Li JJ, Li YS, Fang CH, *et al.* Effects of simvastatin within two weeks on anti-inflammatory
25 cytokine interleukin 10 in patients with unstable angina. *Heart.* 2006;92:529-30.
26
27
- 28
29 12. Cui CJ, Li S, Li JJ. PCSK9 and its modulation. *Clin Chim Acta.* 2015;440:79-86.
30
31
- 32
33 13. Li S, Li JJ. PCSK9: A key factor modulating atherosclerosis. *J Atheroscler Thromb.*
34 2015;22:221-30.
35
36
- 37
38 14. Li S, Zhang Y, Xu RX, *et al.* Proprotein convertase subtilisin-kexin type 9 as a biomarker for
39 the severity of coronary artery disease. *Ann Med.* 2015;47:386-93.
40
41
- 42
43 15. Roth EM, McKenney JM, Hanotin C, *et al.* Atorvastatin with or without an antibody to
44 PCSK9 in primary hypercholesterolemia. *N Engl J Med.* 2012;367:1891-900.
45
46
- 47
48 16. Giunzioni I, Tavori H, Covarrubias R, *et al.* Local effects of human PCSK9 on the
49 atherosclerotic lesion. *J Pathol.* 2016;238:52-62.
50
51
- 52
53 17. Kuhnast S, van der Hoorn JW, Pieterman EJ, *et al.* Alirocumab inhibits atherosclerosis,
54 improves the plaque morphology, and enhances the effects of a statin. *J Lipid Res.*
55 2014;55:2103-12.
56
57

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
18. Sahebkar A, Di Giosia P, Stamerra CA, *et al.* Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms. *Br J Clin Pharmacol.* 2016;81:1175-90.
 19. Gencer B, Montecucco F, Nanchen D, *et al.* Prognostic value of PCSK9 levels in patients with acute coronary syndromes. *Eur Heart J.* 2016;37:546-53.
 20. Kastelein JJ, Nissen SE, Rader DJ, *et al.* Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study. *Eur Heart J.* 2016;37:1360-9.
 21. Moher D, Shamseer L, Clarke M, *et al.* Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev.* 2015;4:1.
 22. Raal F, Scott R, Somaratne R, *et al.* Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. *Circulation.* 2012;126:2408-17.
 23. Raal FJ, Stein EA, Dufour R, *et al.* PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. *Lancet.* 2015;385:331-40.
 24. Stein EA, Gipe D, Bergeron J, *et al.* Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. *Lancet.* 2012;380:29-36.

- 1
2
3
4 25. Blom DJ, Hala T, Bolognese M, *et al.* A 52-week placebo-controlled trial of evolocumab in
5
6 hyperlipidemia. *N Engl J Med.* 2014;370:1809-19.
7
8
9 26. Stroes E, Colquhoun D, Sullivan D, *et al.* Anti-PCSK9 antibody effectively lowers cholesterol
10
11 in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3
12
13 clinical trial of evolocumab. *J Am Coll Cardiol.* 2014;63:2541-2548.
14
15
16 27. Raal FJ, Honarpour N, Blom DJ, *et al.* Inhibition of PCSK9 with evolocumab in homozygous
17
18 familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind,
19
20 placebo-controlled trial. *Lancet.* 2015;385:341-50.
21
22
23 28. Cannon CP, Cariou B, Blom D, *et al.* Efficacy and safety of alirocumab in high cardiovascular
24
25 risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated
26
27 doses of statins: the ODYSSEY COMBO II randomized controlled trial. *Eur Heart J.*
28
29 2015;36:1186-94.
30
31
32
33 29. Nicholls SJ, Puri R, Anderson T, *et al.* Effect of Evolocumab on Progression of Coronary
34
35 Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. *JAMA.*
36
37 2016;316:2373-84.
38
39
40 30. Baruch A, Mosesova S, Davis JD, *et al.* Effects of RG7652, a Monoclonal Antibody Against
41
42 PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High
43
44 Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study).
45
46
47
48 *Am J Cardiol.* 2017;119:1576-83.
49
50
51 31. Wong BW, Meredith A, Lin D, *et al.* The biological role of inflammation in atherosclerosis.
52
53 *Can J Cardiol.* 2012;28:631-41.
54
55
56 32. Ridker PM, Cushman M, Stampfer MJ, *et al.* Inflammation, aspirin, and the risk of
57
58
59
60

- 1
2
3 cardiovascular disease in apparently healthy men. *N Engl J Med.* 1997; 336:973-9.
4
5
6 33. Rost NS, Wolf PA, Kase CS, *et al.* Plasma concentration of C-reactive protein and risk of
7
8 ischemic stroke and transient ischemic attack: the Framingham study. *Stroke.* 2001;32:2575-9.
9
10
11 34. Cesari M, Penninx BW, Newman AB, *et al.* Inflammatory markers and onset of
12
13 cardiovascular events: results from the Health ABC study. *Circulation.* 2003;108:2317-22.
14
15
16 35. Li L, Roumeliotis N, Sawamura T, *et al.* C-reactive protein enhances LOX-1 expression in
17
18 human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial
19
20 dysfunction. *Circ Res.* 2004;95:877-83.
21
22
23 36. Paffen E, DeMaat MP. C-reactive protein in atherosclerosis: A causal factor? *Cardiovasc Res.*
24
25 2006;71:30-9.
26
27
28 37. Ridker PM, Danielson E, Fonseca FA, *et al.* Rosuvastatin to prevent vascular events in men
29
30 and women with elevated C-reactive protein. *N Engl J Med.* 2008;359:2195-207.
31
32
33 38. Zhou X, He W, Huang Z, *et al.* Genetic deletion of low density lipoprotein receptor impairs
34
35 sterol-induced mouse macrophage ABCA1 expression. A new SREBP1-dependent
36
37 mechanism. *J Biol Chem.* 2008;283:2129-38.
38
39
40 39. Tavori H, Giunzioni I, Predazzi IM, *et al.* Human PCSK9 promotes hepatic lipogenesis and
41
42 atherosclerosis development via apoE- and LDLR-mediated mechanisms. *Cardiovasc Res.*
43
44 2016;110:268-78.
45
46
47 40. Li S, Guo YL, Xu RX, *et al.* Association of plasma PCSK9 levels with white blood cell count
48
49 and its subsets in patients with stable coronary artery disease. *Atherosclerosis.*
50
51 2014;234:441-445.
52
53
54
55 41. Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, *et al.* PCSK9 in relation to coronary
56
57

- 1
2
3 plaque inflammation: Results of the ATHEROREMO-IVUS study. *Atherosclerosis*.
4
5
6 2016;248:117-22.
7
- 8 42. Chan DC, Pang J, McQuillan BM, *et al*. Plasma Proprotein Convertase Subtilisin Kexin Type
9
10 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults. *Heart Lung*
11
12 *Circ*.2016;25:520-5.
13
14
- 15 43. Tang Z, Jiang L, Peng J, *et al*. PCSK9 siRNA suppresses the inflammatory response induced
16
17 by oxLDL through inhibition of NF-kappaB activation in THP-1-derived macrophages. *Int J*
18
19 *Mol Med*. 2012;30:931-8.
20
21
- 22 44. Tang ZH, Peng J, Ren Z, *et al*. New role of PCSK9 in atherosclerotic inflammation promotion
23
24 involving the TLR4/NF-kappaB pathway. *Atherosclerosis*. 2017;262:113-22.
25
26
- 27 45. Landlinger C, Pouwer MG, Juno C, *et al*. The AT04A vaccine against proprotein convertase
28
29 subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in
30
31 APOE*3Leiden.CETP mice. *Eur Heart J*.2017;38:2499-507.
32
33
- 34 46. Bernelet Moens SJ, Neele AE, Kroon J, *et al*. PCSK9 monoclonal antibodies reverse the
35
36 pro-inflammatory profile of monocytes in familial hypercholesterolaemia. *Eur Heart J*.
37
38 2017;38:1584-93.
39
40
- 41 47. Ridker PM, Rifai N, Pfeffer MA, *et al*. Inflammation, pravastatin, and the risk of coronary
42
43 events after myocardial infarction in patients with average cholesterol levels. Cholesterol and
44
45 Recurrent Events (CARE) Investigators. *Circulation*. 1998;98:839-44.
46
47
- 48 48. Ridker PM, Rifai N, Clearfield M, *et al*. Measurement of C-reactive protein for the targeting
49
50 of statin therapy in the primary prevention of acute coronary events. *N Engl J Med*.
51
52 2001;344:1959-65.
53
54
55
56
57
58
59
60

Tables

Table 1. Study characteristics of included randomized controlled trials.

Study	Year	Phase	Inclusion criteria	Patients N	Arm	Mean hs-CRP at baseline mg/L	Mean age (years)	Male %	% LDL-C reduction	Drugs/control	Treatment duration	Jadad Score
RUTHERFORD	2012	II	HeFH	167	(1)	1.09±1.37	47.6	54.5	42.7	E:350mg/PBO, Q4W	12W	5
					(2)	1.07±1.24	51.8	62.5	55.2	E:420mg/PBO, Q4W	12W	
Stein EA 2012	2012	II	HeFH	77	(1)	1.40±1.78	56.3	81.3	67.9	A:150mg /PBO, Q2W	12W	5
					(2)	0.60±0.82	51.3	60.0	28.9	A:150mg /PBO, Q4W	12W	
					(3)	0.70±1.48	52.9	56.3	31.5	A:200mg /PBO, Q4W	12W	5
					(4)	0.70±0.59	54.3	46.7	42.5	A:300mg /PBO, Q4W	12W	
DESCARTES	2014	II	HC	894	(1)	2.00±3.70	50.7	47.3	51.5	E:420 mg/ PBO, Q4W	52W	5
					(2)	1.00±1.48	57.2	42.9	54.7	E:420 mg+ATV10 mg/ PBO, Q4W	52W	
					(3)	1.00±1.48	57.8	52.4	46.7	E:420 mg+ATV80 mg/ PBO, Q4W	52W	
					(4)	1.00±1.48	54.2	55.6	46.8	E:420 mg+ATV80 mg+ Eze10mg / PBO, Q4W	52W	
GAUSS-2	2014	III	HC	307	(1)	1.40±2.00	61.0	55.3	56.1	E:140 mg/ Eze, Q2W	12W	4
					(2)	1.80±1.78	63.0	54.9	52.6	E:420 mg/ Eze, Q4W	12W	
RUTHERFORD-2	2014	III	HeFH	329	(1)	0.92±1.03	52.6	40.0	61.3	E:140 mg /PBO,Q2W	12W	4
					(2)	1.04±1.24	51.9	41.8	55.7	E:420 mg /PBO,Q4W	12W	
TESLA Part B	2014	III	HoFH	49		0.70±1.04	31.0	51.5	23.1	E:140 mg /PBO, Q4W	12W	4
ODYSSEY COMBO II	2015	III	HC	720	(1)	3.58±7.78	61.7	75.2	50.6	A: 75mg /Eze, Q2W	24W	4
					(2)	3.58±7.78	61.7	75.2	51.8	A: 75mg /Eze, Q2W	52W	
GLAGOV	2016	III	HC	968		1.60±1.93	59.8	72.1	34.6	E:420 mg /PBO, Q4W	78W	4
Kastelein 2016	2016	II	HC	519	(1)	1.03±1.41	57.2	51.7	14.9	LY:20mg/PBO, Q4W	16W	4
					(2)	1.34±1.11	57.1	52.3	40.5	LY:120mg/PBO, Q4W	16W	

					(3)	1.63±1.78	59.7	54.7	50.5	LY:300mg /PBO, Q4W	16W	
					(4)	1.39±1.70	59.6	58.1	14.9	LY:100mg /PBO, Q8W	16W	
					(5)	1.10±1.63	58.7	50.6	37.1	LY:300mg /PBO, Q8W	16W	
EQUATOR	2017	II	HC	168	(1)	1.60±2.70	65.0	57.9	23.3	RG:400mg/PBO, Q4W	24W	4
					(2)	2.00±5.90	64.0	51.0	44.3	RG:800mg /PBO,Q8w	24W	

Data presented as mean±SD; LDL-C, low density lipoprotein-cholesterol; hs-CRP, hypersensitive C reactive protein; HC, hypercholesterolemia; HeFH, heterozygous familial hypercholesterolemia; HoFH, homozygous familial hypercholesterolemia; E, Evolocumab; A, Alirocumab; LY: LY3015014; RG, RG7652; PBO, placebo; ATV, atorvastatin; Eze, ezetimibe; W, weeks; Q2W, every 2 weeks; Q4W, every 4 weeks. N, number; SD, standard deviation.

For peer review only

1
2
3
4 **Figure legends**
5

6 **Figure 1.** Flow diagram of selection of studies.
7
8

9
10
11 **Figure 2.** Forest plots depicting the effect of PCSK9-mAbs on hs-CRP.

12 CI=confidence interval, PCSK9-mAbs=PCSK9 monoclonal antibodies, hs-CRP= hypersensitive
13 C-reactive protein
14
15

16
17
18
19 **Figure 3.** Subgroup analyses of the effect of PCSK9-mAbs on hs-CRP.

20 CI=confidence interval. PCSK9-mAb=PCSK9 monoclonal antibody. hs-CRP= hypersensitive
21 C-reactive protein. FH= familial hypercholesterolemia. non-FH= non-familial hypercholesterolemia.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Flow diagram of selection of studies.

153x159mm (300 x 300 DPI)




Figure 2. Forest plots depicting the effect of PCSK9-mAbs on hs-CRP. CI=confidence interval, PCSK9-mAbs=PCSK9 monoclonal antibodies, hs-CRP= hypersensitive C-reactive protein

238x213mm (300 x 300 DPI)






Figure 3. Subgroup analyses of the effect of PCSK9-mAbs on hs-CRP.
 CI=confidence interval. PCSK9-mAb=PCSK9 monoclonal antibody. hs-CRP= hypersensitive C-reactive protein. FH= familial hypercholesterolemia. non-FH= non-familial hypercholesterolemia.

256x133mm (300 x 300 DPI)

Supplementary material

Supplemental Table 1. Quality assessment of included studies using the Jadad scale

Studies	Representation of randomization	Appropriateness of method for randomization	Representation of double blinding	Appropriateness of method for double blinding	Representation of withdrawals	Total Score
RUTHERFORD	1	1	1	1	1	5
Stein EA 2012	1	1	1	1	1	5
DESCARTES	1	1	1	1	1	5
GAUSS-2	1	1	1	0	1	5
RUTHERFORD-2	1	1	1	0	1	4
TESLA Part B	1	1	1	0	1	4
ODYSSEY COMBO II	1	1	1	0	1	4
GLAGOV	1	1	1	0	1	4
Kastelein 2016	1	1	1	0	1	4
EQUATOR	1	1	1	0	1	4

Representation of randomization:0, not randomized or inappropriate method of randomization; 1, the study was described as randomized.


Appropriateness of method for randomization: 0, no information about the method of randomization;1, the method of randomization was described and it was appropriate.

Representation of double blinding: 0, no blind or inappropriate method of blinding; 1, the study was described as double blinding.

Appropriateness of method for double blinding: 0, no information about the method of double blinding;1, the method of double blinding was described and it was appropriate.


Withdrawals and dropouts:0, not describe the follow-up; 1, a description of withdrawals and dropouts.

Supplementary Figure 1. Evaluation of risk of bias in the studies.




View Only

Supplementary Figure 2. Pooled analysis for hs-CRP stratified by PCSK9-mAb types.




WMD= weighted mean difference, CI = confidence interval, PCSK9-mAb= proprotein convertase subtilisin/kexin type 9 monoclonal antibody, hs-CRP=hypersensitive C-reactive protein

Supplementary Figure 3. Pooled analysis for hs-CRP stratified by treatment durations.




WMD=weighted mean difference, CI = confidence interval, hs-CRP=hypersensitive C-reactive protein

Supplementary Figure 4. Pooled analysis for hs-CRP stratified by participant characteristics




WMD= weighted mean difference, CI = confidence interval, hs-CRP=hypersensitive C-reactive protein, FH=familial hypercholesterolemia, non-FH= non-familial hypercholesterolemia

Supplementary Figure 5. Pooled analysis for hs-CRP stratified by of treatment methods.


WMD=weighted mean difference, CI = confidence interval, hs-CRP=hypersensitive C-reactive protein

Supplementary Figure 6. Sensitivity analyses of hs-CRP.




hs-CRP=hypersensitive C-reactive protein

Supplementary Figure 7. Funnel Plots of included studies



Supplementary Figure 8. Meta-regression of baseline age (A), sex (B) and percent change of LDL-C (C).



LDL-C=low density lipoprotein cholesterol



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4-5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	5-6
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6-7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6-7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	7-8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	7-8



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	7-8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	7-8
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	8-9
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	8-9
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	9
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	9-10,22
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	10
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	10-11
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	10
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	10
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	14
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	14
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	15

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

BMJ Open

Impact of PCSK9-monoclonal antibodies on circulating hs-CRP levels: a systematic review and meta-analysis of randomized controlled trials

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022348.R1
Article Type:	Research
Date Submitted by the Author:	22-May-2018
Complete List of Authors:	Cao, Ye-Xuan; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College Li, Sha; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Division of Dyslipidemia Liu, Hui-Hui; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Division of Dyslipidemia Li, Jian-Jun; Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Pharmacology and therapeutics
Keywords:	PCSK9, monoclonal antibody, hs-CRP, meta-analysis

SCHOLARONE™
Manuscripts

1
2
3 **Revised bmjopen-2018-022348**

2018-05-22

4
5
6
7 **Title:** Impact of PCSK9-monoclonal antibodies on circulating hs-CRP levels: a systematic
8 review and meta-analysis of randomized controlled trials
9

10
11
12
13
14
15 **Running Title:** PCSK9-mAb and hs-CRP

16
17
18
19
20 **Authors:** Ye-Xuan Cao, MD*, Sha Li, MD, PhD*, Hui-Hui Liu, MD*, Jian-Jun Li, MD, PhD*
21

22
23
24
25
26 **Affiliations:** *Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu
27 Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical
28 Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing 100037, China.
29

30
31
32
33
34
35
36 **Correspondence:** Professor Jian-Jun Li, MD, PhD, FESC, FACC. Division of Dyslipidemia,
37 State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for
38 Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical
39 College, BeiLiShi Road 167, Beijing 100037, China. Tel: 86+10+88396077; Fax:
40 86+10+88396584. E-mail: lijianjun938@126.com.
41
42
43
44
45

46
47
48
49
50 **Total word count:** 2633

51
52
53 **Number of tables/figures:** tables 1; figures 3
54
55
56

ABSTRACT

Objective To evaluate the potential effect of proprotein convertase subtilisin/kexin type 9 monoclonal antibody (PCSK9-mAb) on high-sensitivity C-reactive (hs-CRP) concentrations.

Design A systematic review and meta-analysis of randomized controlled trials.

Data sources PubMed, MEDLINE, The Cochrane Library databases, ClinicalTrials.gov and recent conferences were searched from inception to May 2018.

Eligibility criteria for selecting studies All randomized controlled trials that reported changes of hs-CRP were included.

Results Ten studies involving 4198 participants were identified. PCSK9-mAbs showed a slight efficacy in reducing hs-CRP (-0.04mg/L, 95%CI:-0.17 to 0.01) but no statistically different. The results did not altered when subgroup analyses were performed including PCSK9-mAb types (Alirocumab:0.12mg/L, 95% CI:-0.18 to 0.43; Evolocumab:0.00 mg/L, 95% CI:-0.07 to 0.07; LY3015014:-0.48mg/L, 95% CI:-1.28 to 0.32; RG7652:0.35mg/L, 95% CI:-0.26 to 0.96), treatment duration ($\leq 12w$:0.00mg/L, 95% CI:-0.07 to 0.07; $>12w$: -0.11mg/L, 95% CI:-0.45 to -0.23), participant characteristics (familial hypercholesterolemia: 0.00mg/L, 95% CI:-0.07 to 0.07; non-familial hypercholesterolemia:0.07mg/L, 95% CI:-0.12 to 0.26; mix:-0.48mg/L, 95%CI:-1.28 to 0.32) and treatment methods (monotherapy: 0.00mg/L, -0.08 to 0.07; combination-therapy: -0.08mg/L, -0.37 to 0.21). Meta-regression analyses suggested no significant linear correlation between baseline age ($p=0.673$), sex ($p=0.645$), and low-density lipoprotein cholesterol reduction ($p=0.339$).

Conclusions Our updated meta-analysis suggested that PCSK9-mAbs had no significant impact on circulating hs-CRP levels irrespective of PCSK9-mAb types, participant characteristics, and treatment duration or methods.

Keywords: PCSK9; monoclonal antibody; hs-CRP; meta-analysis

Strengths and limitations of this study

- This is a comprehensive systematic review and meta-analysis of randomized controlled trials, which is conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.
- We used a broad search strategy and identified 10 studies that reported the changes of high-sensitivity C-reactive protein when proprotein convertase subtilisin/kexin type 9 monoclonal antibody was applied.
- Studies with moderate heterogeneity and lack of individual level data.

Introduction

Cardiovascular disease is the greatest burden of global health, which is mainly characterized by atherosclerosis¹. Atherosclerosis is a chronic and progressive inflammatory disease, including endothelial dysfunction, lipid accumulation in the arterial wall and leukocyte infiltration, which leads to luminal stenosis, plaque rupture and acute coronary syndrome (ACS)². Apart from well-established lipid theory, inflammation also plays an important role in the initiation and progression of atherosclerosis³. Recently, the Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) reported that anti-inflammatory therapy by canakinumab, a therapeutic monoclonal antibody targeting interleukin-1 β , significantly reduced the primary cardiovascular end points⁴. This study attracted attention to the inflammation intervention in cardiovascular medicine again.

C-reactive protein (CRP), especially high-sensitivity CRP (hs-CRP), is the most intensively investigated inflammatory biomarker in cardiovascular field⁵. Increasing studies have confirmed that hs-CRP is a predictor for the progression of atherosclerotic disease and future major adverse cardiovascular events (MACE)^{6,7}. Moreover, previous studies also indicated that hs-CRP played a direct role in the development of atherosclerosis^{8,9}. Therefore, reduction of inflammatory markers such as hs-CRP may be a strategy for decreasing MACE^{10,11}.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is known to target low-density lipoprotein receptor (LDLR) for degradation resulting in elevated plasma low-density lipoprotein cholesterol (LDL-C) levels¹²⁻¹⁴. Recently, it has been reported that PCSK9 monoclonal antibody (PCSK9-mAb), as a novel lipid-lowering drug, can reduce LDL-C by a mean of 70% accompanied with reduction of MACE¹⁵. Although the relation of PCSK9 to LDL-C has been established, its role in inflammation has not been fully understood. Several experimental studies found that PCSK9 could promote the progression of atherosclerosis by

1
2
3 enhancing inflammatory reaction¹⁶. On the other hand, PCSK9 deficiency could alleviate the
4 inflammation reaction¹⁷. Hence, whether PCSK9-mAb can reduce inflammatory marker is
5 clinically of great interest since it was used to treat cardiovascular diseases. A meta-analysis
6 covering 7 randomized controlled trials (RCTs) studies published two years ago suggested
7 that PCSK9-mAbs had no effect on serum hs-CRP¹⁸. However, this meta-analysis may be
8 limited by insufficient subgroup analyses, sample size, and lack of newly published data^{19,20}.
9 Hence, we performed this meta-analysis including all RCTs published till May 2018 to
10 further explore the efficacy of PCSK9-mAbs on circulating hs-CRP levels.
11
12
13
14
15
16
17
18
19
20
21

22 **Methods**

23 *Patient and public involvement statement*

24 Patients and the public were not involved.
25
26
27
28
29
30

31 *Literature search*

32 The present study was designed according to the guidelines of the 2009 Preferred Reporting
33 Items for Systematic Reviews and Meta Analyses (PRISMA) statement²¹. To identify all
34 RCTs assessing the effect of PCSK9-mAbs on circulating hs-CRP levels, we
35 comprehensively searched PubMed, MEDLINE, and the Cochrane Library database and
36 ClinicalTrials.gov up until May 2018. The search terms we used included the followings:
37 (AMG145 or Evolocumab or REGN727 or SAR236553 or Alirocumab or RN316 or
38 bococizumab or RG7652 or LY3015014 or PCSK9 antibody or anti-PCSK9) AND
39 (randomized controlled trial OR randomized OR randomly). Meanwhile, manual search was
40 performed for relevant studies including references lists, relevant review articles and
41 commentaries. No language restriction was used.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Study selection

Original studies met the following criteria would be included: the design was phase 2 or phase 3 double-blind RCTs with longer than 8 weeks treatment duration; human participants were randomly assigned to PCSK9-mAbs group versus control group with or without other lipid-lowering therapy; outcomes included percentage changes of hs-CRP from baseline. Studies were excluded if they were duplicate publications, review articles, non-human studies, observational studies, and lack of adequate information on outcomes or lacking control group. Two investigators (YC and SL) independently screened and selected the eligible studies. Disagreements were resolved by discussion with a third investigator.

Data Extraction

A standardized extraction form was used to extract the following items by two investigators (YC and HL) independently: trial name/first author, year of publication, type of intervention, follow-up period, treatment duration, number of patients, participant characteristics, background lipid-lowering therapy, types and doses of PCSK9-mAbs, LDL and hs-CRP levels at baseline and changes. We included the final reported follow-up point if a trial contains several time points. If necessary, further information was required from correspondence author.

Quality Assessment

We used Cochrane Collaboration's tool and Jadad score to assess the data and the methodological quality of included RCTs. For Cochrane Collaboration's tool, the following items were performed: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective

1
2
3 reporting (reporting bias), and other sources of bias. The judgments were classified as ‘low
4 risk’, ‘high risk’, and ‘unclear risk’ of bias. The 5-point Jadad score included the following
5 items: basis of randomization (0 to 2 points), double blinding (0 to 2 points), and withdrawals
6 /dropouts (0 to 1 points). Studies with a score ≥ 3 points are considered to be high quality.
7 Two investigators (YC and HL) independently assessed the quality of each study.
8 Disagreements were resolved by discussion with a third investigator.
9
10
11
12
13
14
15
16
17

18 ***Data Synthesis and Statistical Analysis***

19
20 All analyses were conducted according to the intention-to-treat principles. For all efficacy
21 outcomes, changes in hs-CRP concentrations were expressed as weighted mean difference
22 (WMD) and 95% confidence interval (CI). All the data were standardized and expressed by
23 mg/mL. Standard deviation could be calculated from CI, interquartile range or standard error
24 according to formulas in the Cochrane Handbook for Systematic Reviews of Interventions if
25 not reported.
26
27
28
29
30
31
32

33 Heterogeneity was assessed by the Cochran Q test and the I^2 statistic. We considered
34 $I^2 < 25\%$ as representing low heterogeneity and $I^2 > 75\%$ as representing at high heterogeneity.
35 Outcomes were calculated by fixed-effects models under no or low to moderate inconsistency
36 ($I^2 < 50\%$); otherwise, the data was pooled based on random-effects models. Subgroups were
37 applied to reduce the heterogeneity if $I^2 \geq 50\%$, such as PCSK9-mAb types, treatment
38 duration, and participant characteristics. In order to explore the resource of heterogeneity,
39 sensitivity analysis was conducted by omitting studies in turn to evaluate the consistency of
40 the results. Meta-regression analyses were performed to evaluate the contribution of
41 participant characteristics and reductions in LDL-C concentrations. Publication bias was
42 assessed with a funnel plot and Egger’s test.
43
44
45
46
47
48
49
50
51
52
53

54 All analyses were conducted with Review Manager Version 5.3 (Copenhagen: The
55
56
57
58
59
60

1
2
3 Nordic Cochrane Centre, The Cochrane Collaboration, Denmark) and Stata 14.0 (Stata
4 Statistical Software: College Station, TX: Stata Corp LP). P value <0.05 was considered to be
5 statistically significant.
6
7
8
9

10 11 **Results**

12 *Study selection and Characteristics*

13
14
15 The initial search identified 575 articles. After excluding duplicate publications and screening
16 the titles and abstracts, 430 were excluded and 145 studies were retrieved for full-text
17 identification. We further excluded 135 studies, of which 58 were pooled or meta-analysis, 2
18 studies were not RCTs and 13 was phase 1 trials, 16 were open label trails and 42 without
19 adequate information. Finally, ten studies were included in this meta-analysis^{20,22-30}. Figure 1
20 shows flow diagram of selection process.
21
22
23
24
25
26
27

28
29 These ten studies were published between 2012 and 2017 from different countries with
30 low risk of bias, of which 5 were phase 2 studies and 5 were phase 3 studies (Table 1). A total
31 of 4198 participants were included, comprising 2728 individuals in the PCSK9-mAb group
32 and 1470 in the control group. Alirocumab (SAR236553/REGN727) was used in 4 arms and
33 11 arms applied Evolocumab (AMG 145). Five arms managed LY3015014 and 2 arms used
34 RG7652. Four trials included patients with familial hypercholesterolemia (FH), of which 3
35 were heterozygous FH (HeFH) and 1 was homozygous FH (HoFH). Most of the treatment
36 duration ranged from 12 to 24 weeks and the longest treatment duration was 78 weeks. Apart
37 from DESCARTES trial which co-administered with atorvastatin, another 9 studies used
38 PCSK9-mAb as monotherapy. Baseline characteristics including circulating hs-CRP levels
39 were similar between PCSK9-mAbs and control groups within each study. The characteristics
40 of these trials and participants are summarized in Table 1. All these studies had a relatively
41 high quality evaluated by the Jadad score and low risk of bias (online supplementary Table 1
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

and online supplementary Figure 1, 3 scores=5, 6 scores=4).

Efficacy outcomes of PCSK9-mAbs on hs-CRP

A total of 4198 participants were included in the analysis of efficacy of PCSK9-mAbs on plasma hs-CRP concentrations before and after treatment. When data were pooled, PCSK9-mAbs showed a slight efficacy in reducing hs-CRP (WMD: -0.04mg/L, 95%CI: -0.17 to 0.01), while no statistical difference was found compared with control treatment (Figure 2). There was a moderate heterogeneity between each study ($I^2=57.4%$, $P=0.0001$), so the random-effect model was selected.

To assess the potential discrepancy, we applied the subgroup analyses based on the characteristics of trials and participants (Figure 3 and online supplementary Figures 2-5). Although the efficacy of LY3015014 was a mild higher (-0.48 mg/L, 95% CI:-1.28 to 0.32), there was no difference between these four antibodies (Alirocumab: 0.12 mg/L, 95% CI: -0.18 to 0.43; Evolocumab: 0.00 mg/L, 95% CI: -0.07 to 0.07; RG7652: 0.35 mg/L, 95% CI: -0.26 to 0.96). When studies were classified by treatment duration, the hs-CRP reduction showed no difference in less than 12-week duration group (0.00 mg/L, 95% CI: -0.07 to 0.07) and above 12-week duration group (-0.11mg/L, 95% CI: -0.45 to -0.23). There was no significant reduction in circulating hs-CRP with use of PCSK9 antibodies compared with control treatment when categorized to participant characteristics (FH: 0.00 mg/L, 95% CI: -0.07 to 0.07; non-FH: 0.07 mg/L, 95% CI: -0.12 to 0.26; mix: -0.48 mg/L, 95%CI: -1.28 to 0.32). The analysis stratified by treatment method also supported the results that no differential effect of PCSK9-mAb therapy on plasma hs-CRP concentrations was observed (monotherapy: 0.00 mg/L, 95%CI: -0.08 to 0.07 vs combination-therapy: -0.08 mg/L, 95%CI: -0.37 to 0.21).

Sensitivity analysis and publication bias

The sensitivity analysis for all outcomes was conducted by gradually removing each study. However, the results did not change meaningfully (online supplementary Figure 6). Neither funnel plots (online supplementary Figure 7) nor Egger's regression test ($p=0.913$) showed publication bias.

Meta-regression analyses

We used meta-regression analyses to assess the relationship between changes in hs-CRP and baseline age, sex, and average LDL changes (online supplementary Figure 8). No statistically significant relationship between baseline age ($p=0.673$), male sex ($p=0.645$), and hs-CRP changes were observed. Likewise, LDL-C lowering effects by PCSK9-mAb therapy had no impact on hs-CRP lowering ($p=0.339$, online supplementary Figure 8).

Discussion

The results of this updated, comprehensive meta-analysis, based on 10 RCTs encompassing 4198 participants, suggested that short-term PCSK9-mAb therapy had no impact on circulating hs-CRP concentrations. In the subgroup analyses, no difference was found between PCSK9-mAb types, participant characteristics, and treatment duration or methods.

Atherosclerosis, a chronic progressive disorder, is characterized by lipid accumulation and chronic inflammation in the arterial wall². Although previous data indicated a positive effects of anti-inflammatory drugs on atherosclerosis in animal studies but no positive data was available in human studies³¹. Fortunately, recent evidence from CANTOS found that canakinumab significantly reduced hs-CRP levels and MACE after follow-up of 3.7 years which may support the inflammatory hypothesis of atherosclerosis⁴. Moreover, ongoing Cardiovascular Inflammation Reduction Trial (CIRT) was also designed to directly test the

1
2
3 inflammatory hypothesis of atherosclerosis by evaluating the effect of methotrexate on
4 adverse cardiovascular outcomes without substantive impact on lipids³². Hence, focusing on
5 inflammation in the development of atherosclerosis may be an unsolved issue and great of
6 interest clinically.
7
8
9

10
11 In fact, increasing studies indicated that hs-CRP could independently predict MACE⁶.
12 Framingham study found that men and women in the highest quartile of CRP respectively
13 had twice and three-times the risk of stroke compared with those in the lowest ones after
14 more than 10-years follow-up³³. The Northern Manhattan Study reported that >3 mg/L CRP
15 was associated with a 1.7-fold increase in cardiovascular outcomes and a 1.55-fold increase
16 in mortality³⁴. Furthermore, it has been demonstrated that hs-CRP also plays a direct and vital
17 role in the development of atherosclerosis. Zwaka et al⁸ found that CRP enhanced the
18 transformation from macrophages to foam cells by increasing the uptake of LDL. CRP was
19 also reported to impair vasodilatation, inhibit the synthesis of nitric oxide synthase, and
20 facilitate the adhesion of monocyte^{35,36}. Based on these evidence, reduction of hs-CRP may
21 be associated with a decrease in MACE. Interestingly, the JUPITER study applied
22 rosuvastatin on individuals with LDL-C levels below 130 mg/dL and hs-CRP levels ≥ 2 mg/L,
23 and suggested a significant reduction in all vascular events³⁷. Although a fact that statins
24 lower LDL-C and proportionately reduce MACE is widely accepted, the hs-CRP reduction by
25 statin administration is also an attractive phenomenon, called as pleiotropic effect of statin.
26 That is the reason why we chose hs-CRP as an inflammatory biomarker to identify whether
27 PCSK9-mAb has an effect on inflammatory status.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47
48 Although the relationship between PCSK9 and LDL-C was well-established, more and
49 more evidence demonstrated its function beyond lipids. In 2010, microarray gene expression
50 analysis suggested that PCSK9 affected not only cholesterol metabolism, but also
51 inflammation³⁸. Experimental studies indicated that PCSK9 could participate in vascular and
52
53
54
55
56

1
2
3 systemic inflammation¹⁶. In transgenic mice expressing human PCSK9 gene, Tavori et al³⁹
4 observed that atherosclerosis lesion size and local Ly6C^{hi} monocytes, the precursors of
5 pro-inflammatory M1 macrophages, significantly increased. Clinical studies further
6 supported this hypothesis. Our previous study found that serum PCSK9 concentrations were
7 independently associated with white blood cell count in patients with stable coronary artery
8 disease, indicating PCSK9 might be involved in the inflammation process⁴⁰.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ATHEROREMO-IVUS study reported a positive linearly association between PCSK9 levels and coronary plaque inflammation including amount of necrotic core tissue and plaque volume⁴¹. On the other hand, data also showed that PCSK9 inhibition could exert an anti-inflammatory effect. Tang et al⁴² reported that PCSK9 small interfering RNA reduced the expression of pro-inflammatory genes through nuclear factor kappa B (NF-κB) pathway. In apoE^{-/-} mice, PCSK9 silencing limited the development of atherosclerosis and decreased the number of macrophages via TLR4/NF-κB signaling pathway⁴³. Besides, AT04A anti-PCSK9 vaccine also got the same results that anti-PCSK9 therapy could reduce vascular inflammation⁴⁴. Recently, Bernelot et al⁴⁵ found that after 24 weeks of treatment with PCSK9-mAbs, the migratory capacity of monocytes and inflammatory responsiveness reduced significantly while anti-inflammatory cytokine levels increased in FH patients. Therefore, we hypothesized that PCSK9-mAbs treatment could reduce hs-CRP in randomized clinical studies. Unfortunately, in our meta-analysis the results showed that PCSK9-mAbs therapy had no effect on decreasing hs-CRP in both FH participants and non-FH individuals.

To explore the potential reasons why PCSK9-mAbs therapy was not benefit from inflammatory marker, named as the reduction of circulating hs-CRP levels, we further performed subgroup analyses. Firstly, we did not observe an impact of PCSK9-mAbs types on hs-CRP, which may exclude the influence of PCSK9-mAbs itself on the inflammatory marker in our meta-analysis. Besides, the same results were also observed in combination of

1
2
3 statins and PCSK9-mAbs group, suggesting that the effects of PCSK9-mAbs therapy on
4
5 hs-CRP is not linked with treatment methods. It is notable that the participants in JUPITER
6
7 trial had high levels of hs-CRP at baseline, while in PCSK9-mAb therapy, initial hs-CRP
8
9 levels were at normal range in recruited individuals. Finally, we did not find a positive effects
10
11 of PCSK9-mAbs therapeutic duration on hs-CRP in this updated analysis. Taken together, we
12
13 may conclude that although PCSK9-mAbs had a powerful ability in lowering LDL-C, they
14
15 had no impact on circulating hs-CRP concentration despite of PCSK9-mAb types, participant
16
17 characteristics, and treatment duration or methods.
18
19
20
21

22 **Limitations**

23
24 There were several limitations in our meta-analysis. Firstly, our results were based on study
25
26 data but not individual data as in most meta-analyses. Secondly, although our meta-analysis is
27
28 an updated one, it is still limited by study numbers, sample size, and therapy duration.
29
30 Moreover, moderate degree of heterogeneity was observed in several comparisons. However,
31
32 there was no publication bias and the results were rather consistent among different
33
34 subgroups. Sensitivity analysis suggested that the pooled WMD were robust. Finally, some
35
36 studies included in this meta-analysis did not provide adequate information about blinding of
37
38 participants and personnel.
39
40
41
42
43

44 **Conclusions**

45
46 In conclusion, the current updated evidence suggested that PCSK9-mAb, a novel powerful
47
48 lipid-lowering drug, had no significant impact on circulating hs-CRP concentrations, whose
49
50 effect did not influenced by PCSK9-mAb types, participant characteristics, and treatment
51
52 duration or methods. Long-term observation may be needed.
53
54
55
56
57
58
59
60

Acknowledgements

Not any.

Contributors

JJL contributed to conception and design, acquisition, analysis, and interpretation, and critically revised the manuscript. YXC contributed to design, acquisition, analysis, and interpretation and drafted the manuscript. SL contributed to acquisition, analysis, and critically revised the manuscript. HHL contributed to analysis, interpretation and critically revised the manuscript. All the authors read and approved the final version of the manuscript.

Funding

This work was partially supported by the Capital Health Development Fund (201614035) and CAMS Major Collaborative Innovation Project (2016-I2M-1-011) awarded to Dr. Jian-Jun Li, MD, PhD. The sponsors had no role in the decision to conduct the meta-analyses, data analysis, or reporting of the results.

Competing interests: None declared.

Patient consent: Not required.

Ethics approval: This research is exempt from ethical approval.

Data sharing statement: No additional data available.

Reference

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. *PLoS Med.* 2006;3:e442.
2. Ross R. Atherosclerosis--an inflammatory disease. *N Engl J Med.* 1999;340:115-26.
3. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. *Clin Chem.* 2008;54:24-38.
4. Ridker PM, Everett BM, Thuren T, *et al.* Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. *N Engl J Med.* 2017;377:1119-31.
5. Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. *Med Hypotheses.* 2004;62:499-506.
6. Li JJ, Li S, Zhang Y, *et al.* Proprotein Convertase Subtilisin/Kexin type 9, C-Reactive Protein, Coronary Severity, and Outcomes in Patients With Stable Coronary Artery Disease: A Prospective Observational Cohort Study. *Medicine.* 2015;94:e2426.
7. Wang A, Liu J, Li C, *et al.* Cumulative Exposure to High-Sensitivity C-Reactive Protein Predicts the Risk of Cardiovascular Disease. *J Am Heart Assoc.* 2017; 6:e005610.
8. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. *Circulation.* 2001;103:1194-7.
9. Zhang YX, Cliff WJ, Schoefl GI, *et al.* Coronary C-reactive protein distribution: its relation to development of atherosclerosis. *Atherosclerosis.* 1999;145:375-9.
10. Li JJ, Fang CH. Effects of 4 weeks of atorvastatin administration on the antiinflammatory cytokine interleukin-10 in patients with unstable angina. *Clin Chem.* 2005;51:1735-8.
11. Li JJ, Li YS, Fang CH, *et al.* Effects of simvastatin within two weeks on

- 1
2
3 anti-inflammatory cytokine interleukin 10 in patients with unstable angina. *Heart*.
4
5 2006;92:529-30.
6
7 12. Cui CJ, Li S, Li JJ. PCSK9 and its modulation. *Clin Chim Acta*. 2015;440:79-86.
8
9 13. Li S, Li JJ. PCSK9: A key factor modulating atherosclerosis. *J Atheroscler Thromb*.
10
11 2015;22:221-30.
12
13 14. Li S, Zhang Y, Xu RX, *et al*. Proprotein convertase subtilisin-kexin type 9 as a
14
15 biomarker for the severity of coronary artery disease. *Ann Med*. 2015;47:386-93.
16
17 15. Roth EM, McKenney JM, Hanotin C, *et al*. Atorvastatin with or without an antibody
18
19 to PCSK9 in primary hypercholesterolemia. *N Engl J Med*. 2012;367:1891-900.
20
21 16. Giunzioni I, Tavori H, Covarrubias R, *et al*. Local effects of human PCSK9 on the
22
23 atherosclerotic lesion. *J Pathol*. 2016;238:52-62.
24
25 17. Kuhnast S, van der Hoorn JW, Pieterman EJ, *et al*. Alirocumab inhibits
26
27 atherosclerosis, improves the plaque morphology, and enhances the effects of a statin.
28
29 *J Lipid Res*. 2014;55:2103-12.
30
31 18. Sahebkar A, Di Giosia P, Stamerra CA, *et al*. Effect of monoclonal antibodies to
32
33 PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16
34
35 randomized controlled treatment arms. *Br J Clin Pharmacol*. 2016;81:1175-90.
36
37 19. Gencer B, Montecucco F, Nanchen D, *et al*. Prognostic value of PCSK9 levels in
38
39 patients with acute coronary syndromes. *Eur Heart J*. 2016;37:546-53.
40
41 20. Kastelein JJ, Nissen SE, Rader DJ, *et al*. Safety and efficacy of LY3015014, a
42
43 monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a
44
45 randomized, placebo-controlled Phase 2 study. *Eur Heart J*. 2016;37:1360-9.
46
47 21. Moher D, Shamseer L, Clarke M, *et al*. Preferred reporting items for systematic
48
49 review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev*. 2015;4:1.
50
51 22. Raal F, Scott R, Somaratne R, *et al*. Low-density lipoprotein cholesterol-lowering
52
53
54
55
56
57
58
59
60

- 1
2
3 effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin
4 type 9 serine protease in patients with heterozygous familial hypercholesterolemia:
5 the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial
6 Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. *Circulation*.
7 2012;126:2408-17.
8
9
10
11
12
13 23. Raal FJ, Stein EA, Dufour R, *et al*. PCSK9 inhibition with evolocumab (AMG 145) in
14 heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised,
15 double-blind, placebo-controlled trial. *Lancet*. 2015;385:331-40.
16
17
18
19
20 24. Stein EA, Gipe D, Bergeron J, *et al*. Effect of a monoclonal antibody to PCSK9,
21 REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with
22 heterozygous familial hypercholesterolaemia on stable statin dose with or without
23 ezetimibe therapy: a phase 2 randomised controlled trial. *Lancet*. 2012;380:29-36.
24
25
26
27
28 25. Blom DJ, Hala T, Bolognese M, *et al*. A 52-week placebo-controlled trial of
29 evolocumab in hyperlipidemia. *N Engl J Med*. 2014;370:1809-19.
30
31
32
33 26. Stroes E, Colquhoun D, Sullivan D, *et al*. Anti-PCSK9 antibody effectively lowers
34 cholesterol in patients with statin intolerance: the GAUSS-2 randomized,
35 placebo-controlled phase 3 clinical trial of evolocumab. *J Am Coll Cardiol*.
36 2014;63:2541-2548.
37
38
39
40
41 27. Raal FJ, Honarpour N, Blom DJ, *et al*. Inhibition of PCSK9 with evolocumab in
42 homozygous familial hypercholesterolaemia (TESLA Part B): a randomised,
43 double-blind, placebo-controlled trial. *Lancet*. 2015;385:341-50.
44
45
46
47
48 28. Cannon CP, Cariou B, Blom D, *et al*. Efficacy and safety of alirocumab in high
49 cardiovascular risk patients with inadequately controlled hypercholesterolaemia on
50 maximally tolerated doses of statins: the ODYSSEY COMBO II randomized
51 controlled trial. *Eur Heart J*. 2015;36:1186-94.
52
53
54
55
56
57
58
59
60

- 1
2
3 29. Nicholls SJ, Puri R, Anderson T, *et al.* Effect of Evolocumab on Progression of
4 Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical
5 Trial. *JAMA*. 2016;316:2373-84.
6
7
8
9 30. Baruch A, Mosesova S, Davis JD, *et al.* Effects of RG7652, a Monoclonal Antibody
10 Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in
11 Patients at High Risk of or With Established Coronary Heart Disease (from the Phase
12 2 EQUATOR Study). *Am J Cardiol*. 2017;119:1576-83.
13
14
15
16
17 31. Ridker PM, Cushman M, Stampfer MJ, *et al.* Inflammation, aspirin, and the risk of
18 cardiovascular disease in apparently healthy men. *N Engl J Med*. 1997; 336:973-9.
19
20
21
22 32. Everett BM, Pradhan AD, Solomon DH, *et al.* Rationale and design of the
23 Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis
24 of atherothrombosis. *Am Heart J*. 2013;166:199-207.
25
26
27
28 33. Rost NS, Wolf PA, Kase CS, *et al.* Plasma concentration of C-reactive protein and risk
29 of ischemic stroke and transient ischemic attack: the Framingham study. *Stroke*.
30 2001;32:2575-9.
31
32
33
34 34. Elkind MS, Luna JM, Moon YP, *et al.* High-sensitivity C-reactive protein predicts
35 mortality but not stroke: the Northern Manhattan Study. *Neurology*.2009;73;1300-7.
36
37
38
39 35. Li L, Roumeliotis N, Sawamura T, *et al.* C-reactive protein enhances LOX-1
40 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive
41 protein-induced endothelial dysfunction. *Circ Res*. 2004;95:877-83.
42
43
44
45 36. Paffen E, DeMaat MP. C-reactive protein in atherosclerosis: A causal factor?
46 *Cardiovasc Res*. 2006;71:30-9.
47
48
49
50 37. Ridker PM, Danielson E, Fonseca FA, *et al.* Rosuvastatin to prevent vascular events in men
51 and women with elevated C-reactive protein. *N Engl J Med*. 2008;359:2195-207.
52
53
54 38. Lan H, Pang L, Smith MM, *et al.* Proprotein convertase subtilisin/kexin type 9
55
56
57
58
59
60

- 1
2
3 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver
4 cells. *Cell Physiol.* 2010. 224(1):273-81.
5
6
7 39. Tavori H, Giunzioni I, Predazzi IM, *et al.* Human PCSK9 promotes hepatic
8 lipogenesis and atherosclerosis development via apoE- and LDLR-mediated
9 mechanisms. *Cardiovasc Res.* 2016;110:268-78.
10
11
12
13 40. Li S, Guo YL, Xu RX, *et al.* Association of plasma PCSK9 levels with white blood
14 cell count and its subsets in patients with stable coronary artery disease.
15
16
17
18
19
20 41. Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, *et al.* PCSK9 in relation to
21 coronary plaque inflammation: Results of the ATHEROREMO-IVUS study.
22
23
24
25
26
27 42. Tang Z, Jiang L, Peng J, *et al.* PCSK9 siRNA suppresses the inflammatory response
28 induced by oxLDL through inhibition of NF-kappaB activation in THP-1-derived
29 macrophages. *Int J Mol Med.* 2012;30:931-8.
30
31
32
33 43. Tang ZH, Peng J, Ren Z, *et al.* New role of PCSK9 in atherosclerotic inflammation
34 promotion involving the TLR4/NF-kappaB pathway. *Atherosclerosis.*
35
36
37
38
39
40 44. Landlinger C, Pouwer MG, Juno C, *et al.* The AT04A vaccine against proprotein
41 convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation,
42 and atherosclerosis in APOE*3Leiden.CETP mice. *Eur Heart J.* 2017;38:2499-507.
43
44
45
46 45. Bernelot Moens SJ, Neele AE, Kroon J, *et al.* PCSK9 monoclonal antibodies reverse
47 the pro-inflammatory profile of monocytes in familial hypercholesterolaemia. *Eur*
48
49
50
51
52
53
54
55
56
57
58
59
60

Tables

Table 1. Study characteristics of included randomized controlled trials.

Study	Year	Phase	Inclusion criteria	Patients N	Arm	Mean hs-CRP at baseline mg/L	Mean age (years)	Male %	% LDL-C reduction	Drugs/control	Treatment duration	Jadad Score
RUTHERFORD ²²	2012	II	HeFH	167	(1)	1.09±1.37	47.6	54.5	42.7	E:350mg/PBO, Q4W	12W	5
					(2)	1.07±1.24	51.8	62.5	55.2	E:420mg/PBO, Q4W		
Stein 2012 ²⁴	2012	II	HeFH	77	(1)	1.40±1.78	56.3	81.3	67.9	A:150mg /PBO, Q2W	12W	5
					(2)	0.60±0.82	51.3	60.0	28.9	A:150mg /PBO, Q4W		
					(3)	0.70±1.48	52.9	56.3	31.5	A:200mg /PBO, Q4W		
					(4)	0.70±0.59	54.3	46.7	42.5	A:300mg /PBO, Q4W		
DESCARTES ²⁵	2014	II	HC	894	(1)	2.00±3.70	50.7	47.3	51.5	E:420 mg/ PBO, Q4W	52W	5
					(2)	1.00±1.48	57.2	42.9	54.7	E:420 mg+ATV10 mg/ PBO, Q4W		
					(3)	1.00±1.48	57.8	52.4	46.7	E:420 mg+ATV80 mg/ PBO, Q4W		
					(4)	1.00±1.48	54.2	55.6	46.8	E:420 mg+ATV80 mg+ Eze10mg / PBO, Q4W		
GAUSS-2 ²⁶	2014	III	HC	307	(1)	1.40±2.00	61.0	55.3	56.1	E:140 mg/ Eze, Q2W	12W	4
					(2)	1.80±1.78	63.0	54.9	52.6	E:420 mg/ Eze, Q4W		
RUTHERFORD-2 ²³	2014	III	HeFH	329	(1)	0.92±1.03	52.6	40.0	61.3	E:140 mg /PBO,Q2W	12W	4
					(2)	1.04±1.24	51.9	41.8	55.7	E:420 mg /PBO,Q4W		
TESLA Part B ²⁷	2014	III	HoFH	49		0.70±1.04	31.0	51.5	23.1	E:140 mg /PBO, Q4W	12W	4
ODYSSEY COMBO II ²⁸	2015	III	HC	720	(1)	3.58±7.78	61.7	75.2	50.6	A: 75mg /Eze, Q2W	24W	4
					(2)	3.58±7.78	61.7	75.2	51.8	A: 75mg /Eze, Q2W	52W	
GLAGOV ²⁹	2016	III	HC	968		1.60±1.93	59.8	72.1	34.6	E:420 mg /PBO, Q4W	78W	4

Kastelein 2016 ²⁰	2016	II	HC	519	(1)	1.03±1.41	57.2	51.7	14.9	LY:20mg/PBO, Q4W	16W	4
					(2)	1.34±1.11	57.1	52.3	40.5	LY:120mg/PBO, Q4W		
					(3)	1.63±1.78	59.7	54.7	50.5	LY:300mg /PBO, Q4W		
					(4)	1.39±1.70	59.6	58.1	14.9	LY:100mg /PBO, Q8W		
					(5)	1.10±1.63	58.7	50.6	37.1	LY:300mg /PBO, Q8W		
EQUATOR ³⁰	2017	II	HC	168	(1)	1.60±2.70	65.0	57.9	23.3	RG:400mg/PBO, Q4W	24W	4
					(2)	2.00±5.90	64.0	51.0	44.3	RG:800mg /PBO,Q8W		

Data presented as mean±SD; LDL-C, low density lipoprotein-cholesterol; hs-CRP, hypersensitive C reactive protein; HC, hypercholesterolemia; HeFH, heterozygous familial hypercholesterolemia; HoFH, homozygous familial hypercholesterolemia; E, Evolocumab; A, Alirocumab; LY: LY3015014; RG, RG7652; PBO, placebo; ATV, atorvastatin; Eze, ezetimibe; W, weeks; Q2W, every 2 weeks; Q4W, every 4 weeks. N, number; SD, standard deviation.

1
2
3
4 **Figure legends**
5

6 **Figure 1.** Flow diagram of selection of studies.
7
8

9
10 **Figure 2.** Forest plots depicting the effect of PCSK9-mAbs on hs-CRP.
11

12 CI=confidence interval, PCSK9-mAb=PCSK9 monoclonal antibody, hs-CRP= hypersensitive C-reactive protein
13
14

15
16 **Figure 3.** Subgroup analyses of the effect of PCSK9-mAbs on hs-CRP.
17

18 CI=confidence interval. PCSK9-mAb=PCSK9 monoclonal antibody. hs-CRP= hypersensitive C-reactive protein.
19

20 FH= familial hypercholesterolemia. non-FH= non-familial hypercholesterolemia.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Flow diagram of selection of studies.

153x159mm (300 x 300 DPI)




Figure 2. Forest plots depicting the effect of PCSK9-mAbs on hs-CRP. CI=confidence interval, PCSK9-mAbs=PCSK9 monoclonal antibodies, hs-CRP= hypersensitive C-reactive protein

238x213mm (300 x 300 DPI)






Figure 3. Subgroup analyses of the effect of PCSK9-mAbs on hs-CRP.
 CI=confidence interval. PCSK9-mAb=PCSK9 monoclonal antibody. hs-CRP= hypersensitive C-reactive protein. FH= familial hypercholesterolemia. non-FH= non-familial hypercholesterolemia.

256x133mm (300 x 300 DPI)

Supplementary material

Supplemental Table 1. Quality assessment of included studies using the Jadad scale

Studies	Representation of randomization	Appropriateness of method for randomization	Representation of double blinding	Appropriateness of method for double blinding	Representation of withdrawals	Total Score
RUTHERFORD	1	1	1	1	1	5
Stein EA 2012	1	1	1	1	1	5
DESCARTES	1	1	1	1	1	5
GAUSS-2	1	1	1	0	1	5
RUTHERFORD-2	1	1	1	0	1	4
TESLA Part B	1	1	1	0	1	4
ODYSSEY COMBO II	1	1	1	0	1	4
GLAGOV	1	1	1	0	1	4
Kastelein 2016	1	1	1	0	1	4
EQUATOR	1	1	1	0	1	4

Representation of randomization:0, not randomized or inappropriate method of randomization; 1, the study was described as randomized.


Appropriateness of method for randomization: 0, no information about the method of randomization;1, the method of randomization was described and it was appropriate.

Representation of double blinding: 0, no blind or inappropriate method of blinding; 1, the study was described as double blinding.

Appropriateness of method for double blinding: 0, no information about the method of double blinding;1, the method of double blinding was described and it was appropriate.


Withdrawals and dropouts:0, not describe the follow-up; 1, a description of withdrawals and dropouts.

Supplementary Figure 1. Evaluation of risk of bias in the studies.




View Only

Supplementary Figure 2. Pooled analysis for hs-CRP stratified by PCSK9-mAb types.




WMD= weighted mean difference, CI = confidence interval, PCSK9-mAb= proprotein convertase subtilisin/kexin type 9 monoclonal antibody, hs-CRP=hypersensitive C-reactive protein

Supplementary Figure 3. Pooled analysis for hs-CRP stratified by treatment durations.




WMD=weighted mean difference, CI = confidence interval, hs-CRP=hypersensitive C-reactive protein

Supplementary Figure 4. Pooled analysis for hs-CRP stratified by participant characteristics




WMD= weighted mean difference, CI = confidence interval, hs-CRP=hypersensitive C-reactive protein, FH=familial hypercholesterolemia, non-FH= non-familial hypercholesterolemia

Supplementary Figure 5. Pooled analysis for hs-CRP stratified by of treatment methods.




WMD=weighted mean difference, CI = confidence interval, hs-CRP=hypersensitive C-reactive protein

Supplementary Figure 6. Sensitivity analyses of hs-CRP.




hs-CRP=hypersensitive C-reactive protein

Supplementary Figure 7. Funnel Plots of included studies



Supplementary Figure 8. Meta-regression of baseline age (A), sex (B) and percent change of LDL-C (C).



LDL-C=low density lipoprotein cholesterol

BMJ Open

Impact of PCSK9-monoclonal antibodies on circulating hs-CRP levels: a systematic review and meta-analysis of randomized controlled trials

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022348.R2
Article Type:	Research
Date Submitted by the Author:	22-Aug-2018
Complete List of Authors:	Cao, Ye-Xuan; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College Li, Sha; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Division of Dyslipidemia Liu, Hui-Hui; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Division of Dyslipidemia Li, Jian-Jun; Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Pharmacology and therapeutics
Keywords:	PCSK9, monoclonal antibody, hs-CRP, meta-analysis

SCHOLARONE™
Manuscripts

1
2
3 **Revised-bmjopen-2018-022348.R2**

2018-08-21

4
5
6
7 **Title:** Impact of PCSK9-monoclonal antibodies on circulating hs-CRP levels: a systematic
8 review and meta-analysis of randomized controlled trials
9

10
11
12 **Running Title:** PCSK9-mAb and hs-CRP
13

14
15
16
17 **Authors:** Ye-Xuan Cao, MD*, Sha Li, MD, PhD*, Hui-Hui Liu, MD*, Jian-Jun Li, MD, PhD*
18
19

20
21
22
23 **Affiliations:** *Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu
24 Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical
25 Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing 100037, China.
26
27
28

29
30
31
32
33 **Correspondence:** Professor Jian-Jun Li, MD, PhD, FESC, FACC. Division of Dyslipidemia,
34 State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for
35 Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical
36 College, BeiLiShi Road 167, Beijing 100037, China. Tel: 86+10+88396077; Fax:
37 86+10+88396584. E-mail: lijianjun938@126.com.
38
39
40
41
42
43

44
45
46
47 **Total word count:** 2673
48

49
50 **Number of tables/figures:** tables 1; figures 3
51
52
53
54
55
56

ABSTRACT

Objective To evaluate the potential effects of proprotein convertase subtilisin/kexin type 9 monoclonal antibody (PCSK9-mAb) on high-sensitivity C-reactive (hs-CRP) concentrations.

Design A systematic review and meta-analysis of randomized controlled trials.

Data sources PubMed, MEDLINE, The Cochrane Library databases, ClinicalTrials.gov and recent conferences were searched from inception to May 2018.

Eligibility criteria for selecting studies All randomized controlled trials that reported changes of hs-CRP were included.

Results Ten studies involving 4198 participants were identified. PCSK9-mAbs showed a slight efficacy in reducing hs-CRP (-0.04mg/L, 95%CI:-0.17 to 0.01) which was not statistically different. The results did not altered when subgroup analyses were performed including PCSK9-mAb types (Alirocumab:0.12mg/L, 95% CI:-0.18 to 0.43; Evolocumab:0.00 mg/L, 95% CI:-0.07 to 0.07; LY3015014:-0.48mg/L, 95% CI:-1.28 to 0.32; RG7652:0.35mg/L, 95% CI:-0.26 to 0.96), treatment duration (≤ 12 w:0.00mg/L, 95% CI:-0.07 to 0.07; >12 w: -0.11mg/L, 95% CI:-0.45 to -0.23), participant characteristics (familial hypercholesterolemia: 0.00mg/L, 95% CI:-0.07 to 0.07; non-familial hypercholesterolemia:0.07mg/L, 95% CI:-0.12 to 0.26; mix:-0.48mg/L, 95%CI:-1.28 to 0.32) and treatment methods (monotherapy: 0.00mg/L, -0.08 to 0.07; combination-therapy: -0.08mg/L, -0.37 to 0.21). Meta-regression analyses suggested no significant linear correlation between baseline age ($p=0.673$), sex ($p=0.645$), and low-density lipoprotein cholesterol reduction ($p=0.339$).

Conclusions Our updated meta-analysis suggested that PCSK9-mAbs had no significant impact on circulating hs-CRP levels irrespective of PCSK9-mAb types, participant characteristics, and treatment duration or methods.

1
2
3 **Keywords:** PCSK9; monoclonal antibody; hs-CRP; meta-analysis
4

5 **Strengths and limitations of this study**
6

- 7 ● This is a comprehensive systematic review and meta-analysis that gives an overview of
8 the effect of proprotein convertase subtilisin/kexin type 9 monoclonal antibody
9 (PCSK9-mAb) on inflammation.
10
11
12
13 ● An extensive systematic literature search identified all available randomized controlled
14 trials that reported the changes of high-sensitivity C-reactive protein using PCSK9-mAb.
15
16
17
18 ● Studies with moderate heterogeneity and lack of individual level data may limit the
19 quality of evidence for this meta-analysis.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Cardiovascular disease is the greatest burden of global health, which is mainly characterized by atherosclerosis¹. Atherosclerosis is a chronic and progressive inflammatory disease, including endothelial dysfunction, lipid accumulation in the arterial wall and leukocyte infiltration, which leads to luminal stenosis, plaque rupture and acute coronary syndrome (ACS)². Apart from well-established lipid theory, inflammation also plays an important role in the initiation and progression of atherosclerosis³. Recently, the Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) reported that anti-inflammatory therapy by canakinumab, a therapeutic monoclonal antibody targeting interleukin-1 β , significantly reduced the primary cardiovascular end points⁴. This study attracted attention to the inflammation intervention in cardiovascular medicine again.

C-reactive protein (CRP), especially high-sensitivity CRP (hs-CRP), is the most intensively investigated inflammatory biomarker in cardiovascular field⁵. Increasing studies have confirmed that hs-CRP is a predictor for the progression of atherosclerotic disease and future major adverse cardiovascular events (MACE)^{6,7}. Moreover, previous studies also indicated that hs-CRP played a direct role in the progression of atherosclerosis^{8,9}. Therefore, reduction of inflammatory markers such as hs-CRP may be a strategy for decreasing MACE^{10,11}.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is known to target low-density lipoprotein receptor (LDLR) for degradation resulting in elevated plasma low-density lipoprotein cholesterol (LDL-C) levels¹²⁻¹⁴. Recently, it has been reported that PCSK9 monoclonal antibody (PCSK9-mAb), as a novel lipid-lowering drug, can reduce LDL-C by a mean of 70% accompanied with reduction of MACE¹⁵. Although the relation of PCSK9 to LDL-C has been established, its role in inflammation has not been fully understood. Several

1
2
3 experimental studies found that PCSK9 could promote the progression of atherosclerosis by
4 enhancing inflammatory reaction¹⁶. On the other hand, PCSK9 deficiency could alleviate the
5 inflammation reaction¹⁷. Hence, whether PCSK9-mAb can reduce inflammatory marker is
6 clinically of great interest since it was used to treat cardiovascular diseases. A meta-analysis
7 covering 7 randomized controlled trials (RCTs) studies published two years ago suggested
8 that PCSK9-mAbs had no effect on serum hs-CRP¹⁸. However, this meta-analysis may be
9 limited by insufficient subgroup analyses, sample size, and lack of newly published data^{19,20}.
10 Hence, we performed this meta-analysis including all RCTs published till May 2018 to
11 further explore the efficacy of PCSK9-mAbs on circulating hs-CRP levels.
12
13
14
15
16
17
18
19
20
21
22
23

24 **Methods**

25 *Literature search*

26
27 The present study is reported according to the guidelines of the 2009 Preferred Reporting
28 Items for Systematic Reviews and Meta Analyses (PRISMA) statement²¹. To identify all
29 RCTs assessing the effect of PCSK9-mAbs on circulating hs-CRP levels, we
30 comprehensively searched PubMed, MEDLINE, and the Cochrane Library database and
31 ClinicalTrials.gov up until May 2018. The search terms we used included the followings:
32 (AMG145 or Evolocumab or REGN727 or SAR236553 or Alirocumab or RN316 or
33 bococizumab or RG7652 or LY3015014 or PCSK9 antibody or anti-PCSK9) AND
34 (randomized controlled trial OR randomized OR randomly). Meanwhile, manual search was
35 performed for relevant studies including references lists, relevant review articles and
36 commentaries (see online supplementary Appendix 1). No language restriction was used.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 *Study selection*

53
54 Original studies met the following criteria would be included: the design was phase 2 or
55
56
57
58
59
60

1
2
3 phase 3 double-blind RCTs with longer than 8 weeks treatment duration; human participants
4 were randomly assigned to PCSK9-mAbs group versus control group with or without other
5 lipid-lowering therapy; outcomes included percentage changes of hs-CRP from baseline.
6
7 Studies were excluded if they were duplicate publications, review articles, non-human studies,
8
9 observational studies, and lack of adequate information on outcomes or lacking control group.
10
11 Two investigators (YC and SL) independently screened and selected the eligible studies.
12
13 Disagreements were resolved by discussion with a third investigator.
14
15
16
17
18
19

20 ***Data Extraction***

21
22 A standardized extraction form was used to extract the following items by two investigators
23 (YC and HL) independently: trial name/first author, year of publication, type of intervention,
24 follow-up period, treatment duration, number of patients, participant characteristics,
25 background lipid-lowering therapy, types and doses of PCSK9-mAbs, LDL-C and hs-CRP
26 levels at baseline and changes. We included the final reported follow-up point if a trial
27 contains several time points. If necessary, further information was required from
28 correspondence author.
29
30
31
32
33
34
35
36
37
38
39

40 ***Quality Assessment***

41
42 We used Cochrane Collaboration's tool and Jadad score to assess the data and the
43 methodological quality of included RCTs. For Cochrane Collaboration's tool, the following
44 items were performed: random sequence generation (selection bias), allocation concealment
45 (selection bias), blinding of participants and personnel (performance bias), blinding of
46 outcome assessment (detection bias), incomplete outcome data (attrition bias), selective
47 reporting (reporting bias), and other sources of bias. The judgments were classified as 'low
48 risk', 'high risk', and 'unclear risk' of bias. The 5-point Jadad score included the following
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 items: basis of randomization (0 to 2 points), double blinding (0 to 2 points), and withdrawals
4 /dropouts (0 to 1 points). Studies with a score ≥ 3 points are considered to be high quality.
5
6
7 Two investigators (YC and HL) independently assessed the quality of each study.
8
9 Disagreements were resolved by discussion with a third investigator.
10

11 12 13 ***Data Synthesis and Statistical Analysis*** 14

15 All analyses were conducted according to the intention-to-treat principles. For all efficacy
16 outcomes, changes in hs-CRP concentrations were expressed as weighted mean difference
17 (WMD) and 95% confidence interval (CI). All the data were standardized and expressed by
18 mg/mL. Standard deviation could be calculated from CI, interquartile range or standard error
19 according to formulas in the Cochrane Handbook for Systematic Reviews of Interventions if
20 not reported.
21
22
23
24
25
26
27

28 Heterogeneity was assessed by the Cochran Q test and the I^2 statistic. We considered
29 $I^2 < 25\%$ as representing low heterogeneity and $I^2 > 75\%$ as representing at high heterogeneity.
30
31 Outcomes were calculated by fixed-effects models under no or low to moderate inconsistency
32 ($I^2 < 50\%$); otherwise, the data was pooled based on random-effects models. Subgroups were
33 applied to reduce the heterogeneity if $I^2 \geq 50\%$, such as PCSK9-mAb types, treatment
34 duration, and participant characteristics. In order to explore the resource of heterogeneity,
35 sensitivity analysis was conducted by omitting studies in turn to evaluate the consistency of
36 the results. Meta-regression analyses were performed to evaluate the contribution of
37 participant characteristics and reductions in LDL-C concentrations. Publication bias was
38 assessed with a funnel plot and Egger's test.
39
40
41
42
43
44
45
46
47
48
49

50 All analyses were conducted with Review Manager Version 5.3 (Copenhagen: The
51 Nordic Cochrane Centre, The Cochrane Collaboration, Denmark) and Stata 14.0 (Stata
52 Statistical Software: College Station, TX: Stata Corp LP). P value < 0.05 was considered to be
53
54
55
56

1
2
3 statistically significant.
4
5

6 7 ***Patient and public involvement statement*** 8

9 Participants and the public sector were not directly involved in the design and conduct of this
10 study.
11
12

13 14 15 **Results**

16 17 ***Study selection and Characteristics*** 18

19 The initial search identified 575 articles. After excluding duplicate publications and screening
20 the titles and abstracts, 430 were excluded and 145 studies were retrieved for full-text
21 identification. We further excluded 135 studies, of which 58 were pooled or meta-analysis, 2
22 studies were not RCTs and 13 was phase 1 trials, 16 were open label trails and 42 without
23 adequate information. Finally, ten studies were included in this meta-analysis^{20,22-30}. Figure 1
24 shows flow diagram of selection process.
25
26
27
28
29
30
31
32

33 These ten studies were published between 2012 and 2017 from different countries with
34 low risk of bias, of which 5 were phase 2 studies and 5 were phase 3 studies (Table 1). A total
35 of 4198 participants were included, comprising 2728 individuals in the PCSK9-mAb group
36 and 1470 in the control group. Alirocumab (SAR236553/REGN727) was used in 4 arms and
37 11 arms applied Evolocumab (AMG 145). Five arms managed LY3015014 and 2 arms used
38 RG7652. Four trials included patients with familial hypercholesterolemia (FH), of which 3
39 were heterozygous FH (HeFH) and 1 was homozygous FH (HoFH). Most of the treatment
40 duration ranged from 12 to 24 weeks and the longest treatment duration was 78 weeks. Apart
41 from DESCARTES trial which co-administered with atorvastatin, another 9 studies used
42 PCSK9-mAb as monotherapy. Baseline characteristics including circulating hs-CRP levels
43 were similar between PCSK9-mAbs and control groups within each study. The characteristics
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 of these trials and participants are summarized in Table 1. All these studies had a relatively
4 high quality evaluated by the Jadad score and low risk of bias (online supplementary Table 1
5 and online supplementary Figure 1, 3 scores=5, 6 scores=4).
6
7
8
9

11 ***Efficacy outcomes of PCSK9-mAbs on hs-CRP***

12
13 A total of 4198 participants were included in the analysis of efficacy of PCSK9-mAbs on
14 plasma hs-CRP concentrations before and after treatment. When data were pooled,
15 PCSK9-mAbs showed a slight efficacy in reducing hs-CRP (WMD: -0.04mg/L, 95%CI: -0.17
16 to 0.01), while no statistical difference was found compared with control treatment (Figure 2).
17
18 There was a moderate heterogeneity between each study ($I^2=57.4%$, $p=0.0001$), so the
19 random-effect model was selected.
20
21
22
23
24
25

26 To assess the potential discrepancy, we applied the subgroup analyses based on the
27 characteristics of trials and participants (Figure 3 and online supplementary Figures 2-5).
28 Although the efficacy of LY3015014 was a mild higher (-0.48 mg/L, 95% CI:-1.28 to 0.32),
29 there was no difference between these four antibodies (Alirocumab: 0.12 mg/L, 95% CI:
30 -0.18 to 0.43; Evolocumab: 0.00 mg/L, 95% CI: -0.07 to 0.07; RG7652: 0.35 mg/L, 95% CI:
31 -0.26 to 0.96). When studies were classified by treatment duration, the hs-CRP reduction
32 showed no difference in less than 12-week duration group (0.00 mg/L, 95% CI: -0.07 to 0.07)
33 and above 12-week duration group (-0.11mg/L, 95% CI: -0.45 to -0.23). There was no
34 significant reduction in circulating hs-CRP with use of PCSK9 antibodies compared with
35 control treatment when categorized to participant characteristics (FH: 0.00 mg/L, 95% CI:
36 -0.07 to 0.07; non-FH: 0.07 mg/L, 95% CI: -0.12 to 0.26; mix: -0.48 mg/L, 95%CI: -1.28 to
37 0.32). The analysis stratified by treatment method also supported the results that no
38 differential effect of PCSK9-mAb therapy on plasma hs-CRP concentrations was observed
39 (monotherapy: 0.00 mg/L, 95%CI: -0.08 to 0.07 vs combination-therapy: -0.08 mg/L, 95%CI:
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 -0.37 to 0.21).
4
5

6 7 ***Sensitivity analysis and publication bias*** 8

9 The sensitivity analysis for all outcomes was conducted by gradually removing each study.
10 However, the results did not change meaningfully (online supplementary Figure 6). Neither
11 funnel plots (online supplementary Figure 7) nor Egger's regression test ($p=0.913$) showed
12 publication bias.
13
14
15
16
17

18 19 20 ***Meta-regression analyses*** 21

22 We used meta-regression analyses to assess the relationship between changes in hs-CRP and
23 baseline age, sex, and average LDL-C changes (online supplementary Figure 8). No
24 statistically significant relationship between baseline age ($p=0.673$), male sex ($p=0.645$), and
25 hs-CRP changes were observed. Likewise, LDL-C lowering effects by PCSK9-mAb therapy
26 had no impact on hs-CRP lowering ($p=0.339$, online supplementary Figure 8).
27
28
29
30
31
32
33
34

35 **Discussion** 36

37 The results of this updated, comprehensive meta-analysis, based on 10 RCTs encompassing
38 4198 participants, suggested that short-term PCSK9-mAb therapy had no impact on
39 circulating hs-CRP concentrations. In the subgroup analyses, no difference was found
40 between PCSK9-mAb types, participant characteristics, and treatment duration or methods.
41
42
43
44

45
46 Atherosclerosis, a chronic progressive disorder, is characterized by lipid accumulation
47 and chronic inflammation in the arterial wall². Although previous data indicated a positive
48 effects of anti-inflammatory drugs on atherosclerosis in animal studies but no positive data
49 was available in human studies³¹. Fortunately, recent evidence from CANTOS found that
50 canakinumab significantly reduced hs-CRP levels and MACE after follow-up of 3.7 years
51
52
53
54
55
56

1
2
3 which may support the inflammatory hypothesis of atherosclerosis⁴. Moreover, ongoing
4
5 Cardiovascular Inflammation Reduction Trial (CIRT) was also designed to directly test the
6
7 inflammatory hypothesis of atherosclerosis by evaluating the effect of methotrexate on
8
9 adverse cardiovascular outcomes without substantive impact on lipids³². Hence, focusing on
10
11 inflammation in the development of atherosclerosis may be an unsolved issue and great of
12
13 interest clinically.
14

15
16 In fact, increasing studies indicated that hs-CRP could independently predict MACE⁶.
17
18 Framingham study found that men and women in the highest quartile of CRP respectively
19
20 had twice and three-times the risk of stroke compared with those in the lowest ones after
21
22 more than 10-years follow-up³³. The Northern Manhattan Study reported that >3 mg/L CRP
23
24 was associated with a 1.7-fold increase in cardiovascular outcomes and a 1.55-fold increase
25
26 in mortality³⁴. Furthermore, it has been demonstrated that hs-CRP also plays a direct and vital
27
28 role in the development of atherosclerosis. Zwaka et al⁸ found that CRP enhanced the
29
30 transformation from macrophages to foam cells by increasing the uptake of LDL-C. CRP was
31
32 also reported to impair vasodilatation, inhibit the synthesis of nitric oxide synthase, and
33
34 facilitate the adhesion of monocyte^{35,36}. Based on these evidence, reduction of hs-CRP may
35
36 be associated with a decrease in MACE. Interestingly, the JUPITER study applied
37
38 rosuvastatin on individuals with LDL-C levels below 130 mg/dL and hs-CRP levels ≥ 2 mg/L,
39
40 and suggested a significant reduction in all vascular events³⁷. Although a fact that statins
41
42 lower LDL-C and proportionately reduce MACE is widely accepted, the hs-CRP reduction by
43
44 statin administration is also an attractive phenomenon, called as pleiotropic effect of statin.
45
46 That is the reason why we chose hs-CRP as an inflammatory biomarker to identify whether
47
48 PCSK9-mAb has an effect on inflammatory status.
49
50
51

52
53 Although the relationship between PCSK9 and LDL-C was well-established, more and
54
55 more evidence demonstrated its function beyond lipids. In 2010, microarray gene expression
56
57

1
2
3 analysis suggested that PCSK9 affected not only cholesterol metabolism, but also
4 inflammation³⁸. Experimental studies indicated that PCSK9 could participate in vascular and
5 systemic inflammation¹⁶. In transgenic mice expressing human PCSK9 gene, Tavori et al³⁹
6 observed that atherosclerosis lesion size and local Ly6C^{hi} monocytes, the precursors of
7 pro-inflammatory M1 macrophages, significantly increased. Clinical studies further
8 supported this hypothesis. Our previous study found that serum PCSK9 concentrations were
9 independently associated with white blood cell count in patients with stable coronary artery
10 disease, indicating PCSK9 might be involved in the inflammation process⁴⁰.
11 ATHEROREMO-IVUS study reported a positive linearly association between PCSK9 levels
12 and coronary plaque inflammation including amount of necrotic core tissue and plaque
13 volume⁴¹. On the other hand, data also showed that PCSK9 inhibition could exert an
14 anti-inflammatory effect. Tang et al⁴² reported that PCSK9 small interfering RNA reduced the
15 expression of pro-inflammatory genes through nuclear factor kappa B (NF- κ B) pathway. In
16 apoE-/- mice, PCSK9 silencing limited the development of atherosclerosis and decreased the
17 number of macrophages via TLR4/NF- κ B signaling pathway⁴³. Besides, AT04A anti-PCSK9
18 vaccine also got the same results that anti-PCSK9 therapy could reduce vascular
19 inflammation⁴⁴. Recently, Bernelot et al⁴⁵ found that after 24 weeks of treatment with
20 PCSK9-mAbs, the migratory capacity of monocytes and inflammatory responsiveness
21 reduced significantly while anti-inflammatory cytokine levels increased in FH patients.
22 Therefore, we hypothesized that PCSK9-mAbs treatment could reduce hs-CRP in randomized
23 clinical studies. Unfortunately, in our meta-analysis the results showed that PCSK9-mAbs
24 therapy had no effect on decreasing hs-CRP in both FH participants and non-FH individuals.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 To explore the potential reasons why PCSK9-mAbs therapy was not benefit from
51 inflammatory marker, named as the reduction of circulating hs-CRP levels, we further
52 performed subgroup analyses. Firstly, we did not observe an impact of PCSK9-mAbs types
53
54
55
56
57
58
59
60

1
2
3 on hs-CRP, which may exclude the influence of PCSK9-mAbs itself on the inflammatory
4 marker in our meta-analysis. Besides, the same results were also observed in combination of
5 statins and PCSK9-mAbs group, suggesting that the effects of PCSK9-mAbs therapy on
6 hs-CRP is not linked with treatment methods. It is notable that the participants in JUPITER
7 trial had high levels of hs-CRP at baseline, while in PCSK9-mAb therapy, initial hs-CRP
8 levels were at normal range in recruited individuals. Finally, we did not find a positive effects
9 of PCSK9-mAbs therapeutic duration on hs-CRP in this updated analysis. Taken together, we
10 may conclude that although PCSK9-mAbs had a powerful ability in lowering LDL-C, they
11 had no impact on circulating hs-CRP concentration despite of PCSK9-mAb types, participant
12 characteristics, and treatment duration or methods.
13
14
15
16
17
18
19
20
21
22
23
24
25

26 **Limitations**

27
28 There were several limitations in our meta-analysis. Firstly, our results were based on study
29 data but not individual data as in most meta-analyses. Secondly, although our meta-analysis is
30 an updated one, it is still limited by study numbers, sample size, and therapy duration.
31 Moreover, moderate degree of heterogeneity was observed in several comparisons. However,
32 there was no publication bias and the results were rather consistent among different
33 subgroups. Sensitivity analysis suggested that the pooled WMD were robust. Finally, some
34 studies included in this meta-analysis did not provide adequate information about blinding of
35 participants and personnel.
36
37
38
39
40
41
42
43
44
45
46
47

48 **Conclusions**

49
50 In conclusion, the current updated evidence suggested that PCSK9-mAb, a novel powerful
51 lipid-lowering drug, had no significant impact on circulating hs-CRP concentrations, whose
52 effect did not influenced by PCSK9-mAb types, participant characteristics, and treatment
53
54
55
56
57
58
59
60

1
2
3 duration or methods. Long-term observation may be needed.

4 **Acknowledgements**

5
6
7 Not any.

10 11 **Contributors**

12
13 JJJ contributed to conception and design, acquisition, analysis, and interpretation, and
14 critically revised the manuscript. YXC contributed to design, acquisition, analysis, and
15 interpretation and drafted the manuscript. SL contributed to acquisition, analysis, and
16 critically revised the manuscript. HHL contributed to analysis, interpretation and critically
17 revised the manuscript. All the authors read and approved the final version of the manuscript.
18
19
20
21
22
23
24
25

26 27 **Funding**

28 This work was partially supported by the Capital Health Development Fund (201614035) and
29 CAMS Major Collaborative Innovation Project (2016-I2M-1-011) awarded to Dr. Jian-Jun Li,
30 MD, PhD. The sponsors had no role in the decision to conduct the meta-analyses, data
31 analysis, or reporting of the results.
32
33
34
35
36
37
38
39

40 **Competing interests:** None declared.

41
42
43
44 **Patient consent:** Not required.

45
46
47
48 **Ethics approval:** This research is exempt from ethical approval.

49
50
51
52 **Data sharing statement:** No additional data available.

Reference

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. *PLoS Med*. 2006;3:e442.
2. Ross R. Atherosclerosis--an inflammatory disease. *N Engl J Med*. 1999;340:115-26.
3. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. *Clin Chem*. 2008;54:24-38.
4. Ridker PM, Everett BM, Thuren T, *et al*. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. *N Engl J Med*. 2017;377:1119-31.
5. Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. *Med Hypotheses*. 2004;62:499-506.
6. Li JJ, Li S, Zhang Y, *et al*. Proprotein Convertase Subtilisin/Kexin type 9, C-Reactive Protein, Coronary Severity, and Outcomes in Patients With Stable Coronary Artery Disease: A Prospective Observational Cohort Study. *Medicine*. 2015;94:e2426.
7. Wang A, Liu J, Li C, *et al*. Cumulative Exposure to High-Sensitivity C-Reactive Protein Predicts the Risk of Cardiovascular Disease. *J Am Heart Assoc*. 2017; 6:e005610.
8. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. *Circulation*. 2001;103:1194-7.
9. Zhang YX, Cliff WJ, Schoefl GI, *et al*. Coronary C-reactive protein distribution: its relation to development of atherosclerosis. *Atherosclerosis*. 1999;145:375-9.
10. Li JJ, Fang CH. Effects of 4 weeks of atorvastatin administration on the antiinflammatory cytokine interleukin-10 in patients with unstable angina. *Clin Chem*. 2005;51:1735-8.

11. Li JJ, Li YS, Fang CH, *et al.* Effects of simvastatin within two weeks on anti-inflammatory cytokine interleukin 10 in patients with unstable angina. *Heart*. 2006;92:529-30.
12. Cui CJ, Li S, Li JJ. PCSK9 and its modulation. *Clin Chim Acta*. 2015;440:79-86.
13. Li S, Li JJ. PCSK9: A key factor modulating atherosclerosis. *J Atheroscler Thromb*. 2015;22:221-30.
14. Li S, Zhang Y, Xu RX, *et al.* Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease. *Ann Med*. 2015;47:386-93.
15. Roth EM, McKenney JM, Hanotin C, *et al.* Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. *N Engl J Med*. 2012;367:1891-900.
16. Giunzioni I, Tavori H, Covarrubias R, *et al.* Local effects of human PCSK9 on the atherosclerotic lesion. *J Pathol*. 2016;238:52-62.
17. Kuhnast S, van der Hoorn JW, Pieterman EJ, *et al.* Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. *J Lipid Res*. 2014;55:2103-12.
18. Sahebkar A, Di Giosia P, Stamerra CA, *et al.* Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms. *Br J Clin Pharmacol*. 2016;81:1175-90.
19. Gencer B, Montecucco F, Nanchen D, *et al.* Prognostic value of PCSK9 levels in patients with acute coronary syndromes. *Eur Heart J*. 2016;37:546-53.
20. Kastelein JJ, Nissen SE, Rader DJ, *et al.* Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study. *Eur Heart J*. 2016;37:1360-9.
21. Moher D, Shamseer L, Clarke M, *et al.* Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev*. 2015;4:1.

- 1
2
3 22. Raal F, Scott R, Somaratne R, *et al.* Low-density lipoprotein cholesterol-lowering
4 effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin
5 type 9 serine protease in patients with heterozygous familial hypercholesterolemia:
6 the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial
7 Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. *Circulation.*
8 2012;126:2408-17.
9
10
11
12
13
14
15
16 23. Raal FJ, Stein EA, Dufour R, *et al.* PCSK9 inhibition with evolocumab (AMG 145) in
17 heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised,
18 double-blind, placebo-controlled trial. *Lancet.* 2015;385:331-40.
19
20
21
22 24. Stein EA, Gipe D, Bergeron J, *et al.* Effect of a monoclonal antibody to PCSK9,
23 REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with
24 heterozygous familial hypercholesterolaemia on stable statin dose with or without
25 ezetimibe therapy: a phase 2 randomised controlled trial. *Lancet.* 2012;380:29-36.
26
27
28
29
30
31 25. Blom DJ, Hala T, Bolognese M, *et al.* A 52-week placebo-controlled trial of
32 evolocumab in hyperlipidemia. *N Engl J Med.* 2014;370:1809-19.
33
34
35
36 26. Stroes E, Colquhoun D, Sullivan D, *et al.* Anti-PCSK9 antibody effectively lowers
37 cholesterol in patients with statin intolerance: the GAUSS-2 randomized,
38 placebo-controlled phase 3 clinical trial of evolocumab. *J Am Coll Cardiol.*
39 2014;63:2541-2548.
40
41
42
43
44 27. Raal FJ, Honarpour N, Blom DJ, *et al.* Inhibition of PCSK9 with evolocumab in
45 homozygous familial hypercholesterolaemia (TESLA Part B): a randomised,
46 double-blind, placebo-controlled trial. *Lancet.* 2015;385:341-50.
47
48
49
50 28. Cannon CP, Cariou B, Blom D, *et al.* Efficacy and safety of alirocumab in high
51 cardiovascular risk patients with inadequately controlled hypercholesterolaemia on
52 maximally tolerated doses of statins: the ODYSSEY COMBO II randomized
53
54
55
56
57
58
59
60

- 1
2
3 controlled trial. *Eur Heart J*. 2015;36:1186-94.
4
5 29. Nicholls SJ, Puri R, Anderson T, *et al*. Effect of Evolocumab on Progression of
6
7 Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical
8
9 Trial. *JAMA*. 2016;316:2373-84.
10
11 30. Baruch A, Mosesova S, Davis JD, *et al*. Effects of RG7652, a Monoclonal Antibody
12
13 Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in
14
15 Patients at High Risk of or With Established Coronary Heart Disease (from the Phase
16
17 2 EQUATOR Study). *Am J Cardiol*. 2017;119:1576-83.
18
19
20 31. Ridker PM, Cushman M, Stampfer MJ, *et al*. Inflammation, aspirin, and the risk of
21
22 cardiovascular disease in apparently healthy men. *N Engl J Med*. 1997; 336:973-9.
23
24 32. Everett BM, Pradhan AD, Solomon DH, *et al*. Rationale and design of the
25
26 Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis
27
28 of atherothrombosis. *Am Heart J*. 2013;166:199-207.
29
30
31 33. Rost NS, Wolf PA, Kase CS, *et al*. Plasma concentration of C-reactive protein and risk
32
33 of ischemic stroke and transient ischemic attack: the Framingham study. *Stroke*.
34
35 2001;32:2575-9.
36
37 34. Elkind MS, Luna JM, Moon YP, *et al*. High-sensitivity C-reactive protein predicts
38
39 mortality but not stroke: the Northern Manhattan Study. *Neurology*.2009;73;1300-7.
40
41 35. Li L, Roumeliotis N, Sawamura T, *et al*. C-reactive protein enhances LOX-1
42
43 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive
44
45 protein-induced endothelial dysfunction. *Circ Res*. 2004;95:877-83.
46
47
48 36. Paffen E, DeMaat MP. C-reactive protein in atherosclerosis: A causal factor?
49
50 *Cardiovasc Res*. 2006;71:30-9.
51
52 37. Ridker PM, Danielson E, Fonseca FA, *et al*. Rosuvastatin to prevent vascular events in men
53
54 and women with elevated C-reactive protein. *N Engl J Med*. 2008;359:2195-207.
55
56
57
58
59
60

- 1
2
3 38. Lan H, Pang L, Smith MM, *et al.* Proprotein convertase subtilisin/kexin type 9
4 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver
5 cells. *Cell Physiol.* 2010. 224(1):273-81.
6
7
8
9 39. Tavori H, Giunzioni I, Predazzi IM, *et al.* Human PCSK9 promotes hepatic
10 lipogenesis and atherosclerosis development via apoE- and LDLR-mediated
11 mechanisms. *Cardiovasc Res.* 2016;110:268-78.
12
13
14
15 40. Li S, Guo YL, Xu RX, *et al.* Association of plasma PCSK9 levels with white blood
16 cell count and its subsets in patients with stable coronary artery disease.
17 *Atherosclerosis.* 2014;234:441-445.
18
19
20
21 41. Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, *et al.* PCSK9 in relation to
22 coronary plaque inflammation: Results of the ATHEROREMO-IVUS study.
23 *Atherosclerosis.* 2016;248:117-22.
24
25
26
27 42. Tang Z, Jiang L, Peng J, *et al.* PCSK9 siRNA suppresses the inflammatory response
28 induced by oxLDL through inhibition of NF-kappaB activation in THP-1-derived
29 macrophages. *Int J Mol Med.* 2012;30:931-8.
30
31
32
33 43. Tang ZH, Peng J, Ren Z, *et al.* New role of PCSK9 in atherosclerotic inflammation
34 promotion involving the TLR4/NF-kappaB pathway. *Atherosclerosis.*
35 2017;262:113-22.
36
37
38
39 44. Landlinger C, Pouwer MG, Juno C, *et al.* The AT04A vaccine against proprotein
40 convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation,
41 and atherosclerosis in APOE*3Leiden.CETP mice. *Eur Heart J.* 2017;38:2499-507.
42
43
44
45 45. Bernelot Moens SJ, Neele AE, Kroon J, *et al.* PCSK9 monoclonal antibodies reverse
46 the pro-inflammatory profile of monocytes in familial hypercholesterolaemia. *Eur*
47 *Heart J.* 2017;38:1584-93.
48
49
50
51
52
53
54
55
56
57
58
59
60

Tables

Table 1. Study characteristics of included randomized controlled trials.

Study	Year	Phase	Inclusion criteria	Patients N	Arm	Mean age (years)	Male %	Mean hs-CRP at baseline mg/L	hs-CRP reduction (mg/L)	% LDL-C reduction	Drugs/control	Treatment duration	Jadad Score
RUTHERFORD ²²	2012	II	HeFH	167	(1)	47.6	54.5	1.09±1.37	-0.06 ± 0.94	42.7	E:350mg/PBO, Q4W	12W	5
					(2)	51.8	62.5	1.07±1.24	0.00 ± 0.30	55.2	E:420mg/PBO, Q4W		
Stein 2012 ²⁴	2012	II	HeFH	77	(1)	56.3	81.3	1.40±1.78	-0.40 ± 2.04	67.9	A:150mg /PBO, Q2W	12W	5
					(2)	51.3	60.0	0.60±0.82	-0.20 ± 0.81	28.9	A:150mg /PBO, Q4W		
					(3)	52.9	56.3	0.70±1.48	0.00 ± 1.29	31.5	A:200mg /PBO, Q4W		
					(4)	54.3	46.7	0.70±0.59	-0.10± 0.84	42.5	A:300mg /PBO, Q4W		
DESCARTES ²⁵	2014	II	HC	894	(1)	50.7	47.3	2.00±3.70	0.00 ± 2.57	51.5	E:420 mg/ PBO, Q4W	52W	5
					(2)	57.2	42.9	1.00±1.48	0.00 ± 1.48	54.7	E:420 mg+ATV10 mg/ PBO, Q4W		
					(3)	57.8	52.4	1.00±1.48	0.00 ± 1.48	46.7	E:420 mg+ATV80 mg/ PBO, Q4W		
					(4)	54.2	55.6	1.00±1.48	0.00 ± 1.48	46.8	E:420 mg+ATV80 mg+ Eze10mg / PBO, Q4W		
GAUSS-2 ²⁶	2014	III	HC	307	(1)	61.0	55.3	1.40±2.00	0.30 ± 2.67	56.1	E:140 mg/ Eze, Q2W	12W	4
					(2)	63.0	54.9	1.80±1.78	-0.30 ± 1.78	52.6	E:420 mg/ Eze, Q4W		
RUTHERFORD-2 ²³	2014	III	HeFH	329	(1)	52.6	40.0	0.92±1.03	-0.05 ± 0.39	61.3	E:140 mg /PBO,Q2W	12W	4
					(2)	51.9	41.8	1.04±1.24	0.03 ± 0.73	55.7	E:420 mg /PBO,Q4W		
TESLA Part B ²⁷	2014	III	HoFH	49		31.0	51.5	0.70±1.04	-0.02 ± 0.52	23.1	E:140 mg /PBO, Q4W	12W	4
ODYSSEY COMBO II ²⁸	2015	III	HC	720	(1)	61.7	75.2	3.58±7.78	-0.39 ± 6.95	50.6	A: 75mg /Eze, Q2W	24W	4
					(2)	61.7	75.2	3.58±7.78	-0.07 ± 8.57	51.8	A: 75mg /Eze, Q2W	52W	
GLAGOV ²⁹	2016	III	HC	968		59.8	72.1	1.60±1.93	-0.40 ± 10.67	60.8	E:420 mg /PBO, Q4W	78W	4

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Kastelein 2016 ²⁰	2016	II	HC	519	(1)	57.2	51.7	1.03±1.41	-0.20 ± 2.07	14.9	LY:20mg/PBO, Q4W	16W	4
					(2)	57.1	52.3	1.34±1.11	1.60 ± 2.00	40.5	LY:120mg/PBO, Q4W		
					(3)	59.7	54.7	1.63±1.78	-0.30 ± 2.00	50.5	LY:300mg /PBO, Q4W		
					(4)	59.6	58.1	1.39±1.70	-0.30 ± 2.07	14.9	LY:100mg /PBO, Q8W		
					(5)	58.7	50.6	1.10±1.63	-0.70 ± 2.07	37.1	LY:300mg /PBO, Q8W		
EQUATOR ³⁰	2017	II	HC	168	(1)	65.0	57.9	1.60±2.70	0.34 ± 1.93	23.3	RG:400mg/PBO, Q4W	24W	4
					(2)	64.0	51.0	2.00±5.90	-0.16 ± 2.92	44.3	RG:800mg /PBO,Q8W		

Data presented as mean±SD; LDL-C, low density lipoprotein-cholesterol; hs-CRP, hypersensitive C reactive protein; HC, hypercholesterolemia; HeFH, heterozygous familial hypercholesterolemia; HoFH, homozygous familial hypercholesterolemia; E, Evolocumab; A, Alirocumab; LY: LY3015014; RG, RG7652; PBO, placebo; ATV, atorvastatin; Eze, ezetimibe; W, weeks; Q2W, every 2 weeks; Q4W, every 4 weeks. N, number; SD, standard deviation.

1
2
3
4 **Figure legends**
5

6 **Figure 1.** Flow diagram of selection of studies.
7
8

9
10 **Figure 2.** Forest plots depicting the effect of PCSK9-mAbs on hs-CRP.
11

12 CI=confidence interval, PCSK9-mAb=PCSK9 monoclonal antibody, hs-CRP= hypersensitive C-reactive protein
13
14

15
16 **Figure 3.** Subgroup analyses of the effect of PCSK9-mAbs on hs-CRP.
17

18 CI=confidence interval. PCSK9-mAb=PCSK9 monoclonal antibody. hs-CRP= hypersensitive C-reactive protein.
19

20 FH= familial hypercholesterolemia. non-FH= non-familial hypercholesterolemia.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Flow diagram of selection of studies.

153x159mm (300 x 300 DPI)




Figure 2. Forest plots depicting the effect of PCSK9-mAbs on hs-CRP. CI=confidence interval, PCSK9-mAbs=PCSK9 monoclonal antibodies, hs-CRP= hypersensitive C-reactive protein

238x213mm (300 x 300 DPI)






Figure 3. Subgroup analyses of the effect of PCSK9-mAbs on hs-CRP.
 CI=confidence interval. PCSK9-mAb=PCSK9 monoclonal antibody. hs-CRP= hypersensitive C-reactive protein. FH= familial hypercholesterolemia. non-FH= non-familial hypercholesterolemia.

256x133mm (300 x 300 DPI)

Supplementary material

Appendix 1. The search string

Medline via Ovid

- 1.exp AMG 145/
- 2.exp Evolocumab/
- 3.exp REGN727/
- 4.exp SAR236553/
- 5.exp Alirocumab/
- 6.exp RN316/
- 7.exp Bococizumab/
- 8.exp RG7652/
- 9.exp LY3015014/
- 10.exp ALN-PCSS/
- 11.exp PCSK9 antibodies/
- 12.exp anti-PCSK9/
- 13.exp Clinical Trial/
- 14.exp Randomized Controlled Trial/
- 15.exp Controlled Clinical Trial/
- 16.exp Random Allocation/
- 17.1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12
- 18.13 OR 14 OR 15 OR 16
- 19.17 AND 18
20. limit 19 to (humans)

Pubmed

"amg145"[Title/Abstract]) OR "Evolocumab"[Title/Abstract]) OR "REGN727"[Title/Abstract])
OR "SAR236553"[Title/Abstract]) OR "Alirocumab"[Title/Abstract]) OR "RN316"[Title/
Abstract]) OR "bococizumab"[Title/Abstract]) OR "RG7652"[Title/Abstract]) OR "LY3015014"
[Title/Abstract]) OR "ALN-PCSSC"[Title/Abstract]) OR "PCSK9 antibodies"[Title/Abstract]) OR
"anti-PCSK9"[Title/ Abstract]) AND randomized controlled trial[Publication Type]) AND
"humans"[MeSH Terms]


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Supplemental Table 1. Quality assessment of included studies using the Jadad scale


Studies	Representation of randomization	Appropriateness of method for randomization	Representation of double blinding	Appropriateness of method for double blinding	Representation of withdrawals	Total Score
RUTHERFORD	1	1	1	1	1	5
Stein EA 2012	1	1	1	1	1	5
DESCARTES	1	1	1	1	1	5
GAUSS-2	1	1	1	0	1	5
RUTHERFORD-2	1	1	1	0	1	4
TESLA Part B	1	1	1	0	1	4
ODYSSEY COMBO II	1	1	1	0	1	4
GLAGOV	1	1	1	0	1	4
Kastelein 2016	1	1	1	0	1	4
EQUATOR	1	1	1	0	1	4

Representation of randomization:0, not randomized or inappropriate method of randomization; 1, the study was described as randomized.
Appropriateness of method for randomization: 0, no information about the method of randomization;1, the method of randomization was described and it was appropriate.
Representation of double blinding: 0, no blind or inappropriate method of blinding; 1, the study was described as double blinding.
Appropriateness of method for double blinding: 0, no information about the method of double blinding;1, the method of double blinding was described and it was appropriate.
Withdrawals and dropouts:0, not describe the follow-up; 1, a description of withdrawals and dropouts.

Supplementary Figure 1. Evaluation of risk of bias in the studies.




Supplementary Figure 2. Pooled analysis for hs-CRP stratified by PCSK9-mAb types.




WMD= weighted mean difference, CI = confidence interval, PCSK9-mAb= proprotein convertase subtilisin/kexin type 9 monoclonal antibody, hs-CRP=hypersensitive C-reactive protein

Supplementary Figure 3. Pooled analysis for hs-CRP stratified by treatment durations.



WMD=weighted mean difference, CI = confidence interval, hs-CRP=hypersensitive C-reactive protein


Supplementary Figure 4. Pooled analysis for hs-CRP stratified by participant characteristics



WMD= weighted mean difference, CI = confidence interval, hs-CRP=hypersensitive C-reactive protein,


FH=familial hypercholesterolemia, non-FH= non-familial hypercholesterolemia

Supplementary Figure 5. Pooled analysis for hs-CRP stratified by of treatment methods.




WMD=weighted mean difference, CI = confidence interval, hs-CRP=hypersensitive C-reactive protein

Supplementary Figure 6. Sensitivity analyses of hs-CRP.




hs-CRP=hypersensitive C-reactive protein

Supplementary Figure 7. Funnel Plots of included studies



Supplementary Figure 8. Meta-regression of baseline age (A), sex (B) and percent change of LDL-C (C).



LDL-C=low density lipoprotein cholesterol

